



ISPOR 20th Annual  
International Meeting  
May 16-20, 2015  
Philadelphia Marriott Downtown  
Philadelphia, PA, USA



# Research Poster Presentations – Session III

Tuesday, May 19, 2015

8:30AM-2:15PM

**Poster Author Discussion Hour:**

1:15PM-2:15PM

Research Poster Presentations – Session III includes the following topics

**PCV – CARDIOVASCULAR DISORDERS** Rows A-G

**PMS – MUSCULAR-SKELETAL DISORDERS** Rows G-M

**PRS – RESPIRATORY-RELATED DISORDERS** Rows M-Q

**PSS – SENSORY SYSTEMS DISORDERS** Rows Q-V

**PUK – URINARY/KIDNEY DISORDERS** Rows V-X

A1 Location of the poster in the poster hall – please refer to last page for a floor plan

pgA10 Location of the abstract as published in *Value in Health* Volume 18, Issue 3

# RESEARCH POSTER PRESENTATIONS - SESSION III

## DISEASE- SPECIFIC STUDIES

### CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies

- PCV1 A1 pgA129 IMPACT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON THE RISK OF CARDIOVASCULAR-RELATED HOSPITALIZATIONS**  
**Kathe NJ**<sup>1</sup>, Shah AB<sup>2</sup>, Said Q<sup>1</sup>,<sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AR, USA, <sup>2</sup>University of Arkansas for Medical Sciences, LITTLE ROCK, AR, USA
- PCV2 A2 pgA129 A STUDY OF ADVERSE DRUG REACTIONS ASSOCIATED WITH ANTIHYPERTENSIVE AGENTS IN A TERTIARY CARE TEACHING HOSPITAL IN CENTRAL NEPAL**  
**Paudel S**, Subedi N, College of Medical Sciences- Teaching Hospital, Chitwan, Nepal
- PCV3 A3 pgA130 A DESCRIPTIVE ANALYSIS OF PATIENT CHARACTERISTICS, BLEEDING AND RECURRENCE RISK AMONG U.S VETERAN PATIENTS DIAGNOSED WITH VENOUS THROMBOEMBOLISM**  
**Xie L**<sup>1</sup>, Du J<sup>1</sup>, Kariburyo MF<sup>1</sup>, Baser O<sup>2</sup>,<sup>1</sup>STATinMED Research, Ann Arbor, MI, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA
- PCV4 A4 pgA130 NOVEL PHARMACIST-GUIDED PHARMACOGENETIC SERVICE LOWERS WARFARIN-RELATED HOSPITALIZATIONS**  
**Kim K**<sup>1</sup>, Gor D<sup>1</sup>, Walton SM<sup>1</sup>, Galanter WL<sup>1</sup>, Duarte J<sup>1</sup>, Krishnan JA<sup>1</sup>, Bauman JL<sup>1</sup>, Cavallari LH<sup>2</sup>, Nutescu EA<sup>1</sup>,<sup>1</sup>University of Illinois at Chicago, Chicago, IL, USA, <sup>2</sup>University of Florida, Gainesville, FL, USA
- PCV5 A5 pgA130 CLINICAL OUTCOMES AND TREATMENT PATTERNS OF VENOUS THROMBOEMBOLISM AMONG CANCER PATIENTS IN A LARGE COMMERCIAL DATABASE**  
**Masseria C**<sup>1</sup>, Kariburyo MF<sup>2</sup>, Mardekian J<sup>1</sup>, Lee T<sup>1</sup>, Phatak H<sup>3</sup>, Baser O<sup>4</sup>, Xie L<sup>2</sup>,<sup>1</sup>Pfizer Inc., New York, NY, USA, <sup>2</sup>STATinMED Research, Ann Arbor, MI, USA, <sup>3</sup>Bristol-Myers Squibb Company, Princeton, NJ, USA, <sup>4</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA
- PCV6 A6 pgA130 CONCOMITANT SLEEP DISORDER SIGNIFICANTLY ENHANCES THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH PSORIASIS**  
**Chiu H**<sup>1</sup>, Chiang Y<sup>2</sup>, Hsieh C<sup>2</sup>, Tsai Y<sup>3</sup>, Huang W<sup>3</sup>, Tsai T<sup>1</sup>,<sup>1</sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>2</sup>National Yang-Ming University, Taipei, Taiwan, <sup>3</sup>National Yang Ming University, Taipei, Taiwan
- PCV7 A7 pgA130 VALIDATION OF HYPERTENSIVE PATIENT IDENTIFICATION AND EFFECT OF VARYING OBSERVATION TIME FROM ADMINISTRATIVE CLAIMS DATA USING ELECTRONIC MEDICAL RECORDS**  
Liu J, Ma Q, Willey V, Rodenberger D, **Barron J**, HealthCore, Inc, Wilmington, DE, USA
- PCV8 A8 pgA131 COMPARATIVE EFFECTIVENESS OF RIVAROXABAN AND STANDARD ANTICOAGULANT THERAPIES FOR PREVENTION OF PRIMARY VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY**  
**Shewale AR**, Martin BC, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- PCV9 A9 pgA131 ESTIMATING THE LIFETIME CLINICAL RISK/BENEFITS OF APIXABAN VERSUS EDOXABAN IN NON-VALVULAR ATRIAL FIBRILLATION**  
**Phatak H**<sup>1</sup>, Dorian P<sup>2</sup>, Kongnakorn T<sup>3</sup>, Lanitis T<sup>4</sup>, Liu X<sup>5</sup>, Mardekian J<sup>6</sup>, Lawrence J<sup>7</sup>, Lip G<sup>8</sup>,<sup>1</sup>Bristol-Myers Squibb Company, Princeton, NJ, USA, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Evidera, Bangkok, Thailand, <sup>4</sup>Evidera, London, UK, <sup>5</sup>Pfizer, New York, NY, USA, <sup>6</sup>Pfizer Inc., New York, NY, USA, <sup>7</sup>BMS, Princeton, NJ, USA, <sup>8</sup>University of Birmingham, Birmingham, UK
- PCV10 A10 pgA131 CARDIOVASCULAR SAFETY WITH THE CONCURRENT USE OF MOOD STABILIZERS OR ATYPICAL ANTIPSYCHOTICS AND STIMULANTS IN CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND BIPOLAR DISORDER**  
**Rane P**, Bali V, Aparasu RR, University of Houston, Houston, TX, USA
- PCV11 A11 pgA131 DISCONTINUATION OF STATIN USE AFTER HEMODIALYSIS AND THE RISK OF CARDIOVASCULAR DISEASES**  
**Liu Y**<sup>1</sup>, Huang W<sup>1</sup>, Chang W<sup>1</sup>, Wen Y<sup>2</sup>, Tsai Y<sup>1</sup>,<sup>1</sup>National Yang Ming University, Taipei, Taiwan, <sup>2</sup>Chang Gung University, Taoyuan, Taiwan
- PCV12 A12 pgA131 THE IMPACT OF RACE ON THE ASSOCIATION BETWEEN A NOVEL GENOTYPE-GUIDED PERSONALIZED WARFARIN SERVICE AND CLINICAL OUTCOMES IN AN ETHNICALLY DIVERSE POPULATION**  
**Manzoor B**<sup>1</sup>, Duarte J<sup>1</sup>, Lee J<sup>1</sup>, Galanter WL<sup>1</sup>, Walton SM<sup>1</sup>, Galanter N<sup>1</sup>, Krishnan JA<sup>1</sup>, Bauman JL<sup>1</sup>, Cavallari LH<sup>2</sup>, Nutescu EA<sup>1</sup>,<sup>1</sup>University of Illinois at Chicago, Chicago, IL, USA, <sup>2</sup>University of Florida, Gainesville, FL, USA
- PCV14 A13 pgA131 EHEALTH IN THE MANAGEMENT OF CHRONIC DISEASES: A REVIEW OF PROGRAM EFFICACY**  
**Kiss N**<sup>1</sup>, Fortier K<sup>2</sup>,<sup>1</sup>Department of Health Economics, Centre for Public Health, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Compass Strategic Consulting, Inc., New Haven, CT, USA
- PCV15 A14 pgA132 COMPARISON OF APIXABAN, DABIGATRAN, RIVAROXABAN, AND EDOXABAN IN THE ACUTE TREATMENT AND PREVENTION OF VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**  
**Cohen AT**<sup>1</sup>, Batson S<sup>2</sup>, Hamilton M<sup>3</sup>, Masseria C<sup>4</sup>, Mitchell S<sup>2</sup>, Phatak H<sup>3</sup>,<sup>1</sup>King's College, London, UK, <sup>2</sup>Abacus

International, Bicester, UK, <sup>3</sup>BMS, Princeton, NJ, USA, <sup>4</sup>Pfizer Inc., New York, NY, USA

- PCV16** A15 pgA132 **EFFICACY AND SAFETY OF AMLODIPINE AND BISOPROLOL IN HYPERTENSION TREATMENT: A SYSTEMATIC REVIEW**  
**Fujii RK<sup>1</sup>**, Restrepo M<sup>2</sup>, Pepe C<sup>3</sup>, Fernandes RA<sup>3</sup>, Haas L<sup>4</sup>, Junqueira M<sup>1</sup>, Merck Serono, São Paulo, Brazil, <sup>2</sup>Merck Serono, Bogota, Colombia, <sup>3</sup>Grupo Resulta, São Paulo, Brazil, <sup>4</sup>ANOVA, Rio de Janeiro, Brazil
- PCV17** A16 pgA132 **EFFECTIVENESS AND COST-EFFECTIVENESS OF CATHETER-DIRECTED THROMBOLYSIS IN MASSIVE PULMONARY EMBOLISM**  
**Kostyuk A<sup>1</sup>**, Akanov A<sup>2</sup>, Garkalov K<sup>1</sup>, Kazakh Medical University for Continuing Education, Astana, Kazakhstan, <sup>2</sup>Astana Medical University, Astana, Kazakhstan
- PCV18** A17 pgA132 **MIPOMERSEN FOR TREATMENT OF HYPERCHOLESTEREMIA: EVIDENCE REVIEW AND META ANALYTIC EVALUATION OF RANDOMIZED CONTROLLED TRIALS**  
**Bardia A<sup>1</sup>**, Garg G<sup>2</sup>, <sup>1</sup>Invaluesys Research, Hyderabad, India, <sup>2</sup>Invaluesys Research, Burgdorf, Germany
- PCV19** A18 pgA132 **THE USE OF LOW MOLECULAR WEIGHT HEPARIN AND PNEUMATIC COMPRESSION DEVICES FOR DEEP VEIN THROMBOSIS PROPHYLAXIS IN MAJOR TRAUMA PATIENTS: A COMPARATIVE EFFECTIVENESS ANALYSIS**  
**Alahmari AK**, Almalki ZS, Guo JJ, University of Cincinnati, Cincinnati, OH, USA
- PCV20** A19 pgA133 **THE ASSOCIATION BETWEEN CHOICE OF BALANCED INTRAVENOUS CRYSTALLOID AND SUBSEQUENT MAJOR IN-HOSPITAL OUTCOMES AMONG ADULT PATIENTS UNDERGOING CARDIAC SURGERY**  
Raghunathan K<sup>1</sup>, **Khangulov VS<sup>2</sup>**, Peyerl FW<sup>2</sup>, Shaw AD<sup>3</sup>, <sup>1</sup>Durham VA Medical Center, Durham, NC, USA, <sup>2</sup>Boston Strategic Partners, Inc., Boston, MA, USA, <sup>3</sup>Vanderbilt University Medical Center, Nashville, TN, USA
- PCV21** A20 pgA133 **MODELLING THE CLINICAL AND ECONOMIC OUTCOMES OF VARIATIONS IN INTENSITY OF VALSARTAN-CENTRIC REGIMENS FOR HYPERTENSION**  
**Alshayban DM**, University of Arizona, Tucson, AZ, USA
- PCV22** A21 pgA133 **COMPARE EARLY MORTALITY AFTER AORTIC VALVE REPLACEMENT WITH MECHANICAL PROSTHETIC VS BIOPROSTHETIC VALVES AMONG MEDICARE BENEFICIARIES**  
**Du D<sup>1</sup>**, McKean S<sup>2</sup>, Kelman JA<sup>3</sup>, Laschinger J<sup>1</sup>, Johnson C<sup>2</sup>, Warnock R<sup>2</sup>, Worrall CM<sup>4</sup>, Sedrakyan A<sup>5</sup>, Encinosa W<sup>6</sup>, MaCurdy TE<sup>2</sup>, Izurieta HS<sup>1</sup>, <sup>1</sup>Food and Drug Administration, Silver Spring, MD, USA, <sup>2</sup>Acumen LLC, Burlingame, CA, USA, <sup>3</sup>CMS, Washington DC, DC, USA, <sup>4</sup>CMS, Baltimore, MD, USA, <sup>5</sup>Weill Cornell Medical College, New York City, NY, USA, <sup>6</sup>Agency for Healthcare Research and Quality, Rockville, MD, USA
- PCV23** B1 pgA133 **COMPARATIVE EFFECTIVENESS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN HEART FAILURE**  
**Sharma M**, Johnson ML, Chen H, Aparasu R, University of Houston, Houston, TX, USA
- PCV24** B2 pgA133 **MULTIFACETED INTERVENTIONS IMPROVE MEDICATION ADHERENCE IN MEDICAID PATIENTS PRESCRIBED HYPOGLYCEMICS, STATINS, AND/OR ANTIHYPERTENSIVES**  
Gao W<sup>1</sup>, **Keleti D<sup>1</sup>**, Donia T<sup>1</sup>, Downey TW<sup>1</sup>, Megargell L<sup>2</sup>, Kreitman J<sup>3</sup>, Michael KE<sup>1</sup>, Gelzer AD<sup>1</sup>, <sup>1</sup>The AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA, <sup>2</sup>PerformRx, Philadelphia, PA, USA, <sup>3</sup>AmeriHealth Caritas Pennsylvania, Harrisburg, PA, USA
- PCV25** B3 pgA133 **EVALUATION OF BLEEDING OUTCOMES LINKED TO NEW ORAL ANTICOAGULANTS: REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)**  
**Jacobs DM**, Hempel C, Feuerstein S, University at Buffalo, Buffalo, NY, USA
- PCV26** B4 pgA134 **ANTIHYPERTENSIVE DRUG UTILIZATION IN ELDERLY OUTPATIENTS IN SERBIA**  
**Tomas A**, Horvat O, Paut Kusturica M, Tomic Z, Ban M, Sabo A, Faculty of Medicine, Novi Sad, Serbia and Montenegro
- PCV27** B5 pgA134 **USE OF SELECTIVE-SEROTONIN REUPTAKE INHIBITORS AND PLATELET AGGREGATION INHIBITORS AMONG INDIVIDUALS WITH CO-OCCURRING HEART DISEASE AND DEPRESSION OR ANXIETY**  
**Thornton JD**, Agarwal P, Sambamoorthi U, West Virginia University, Morgantown, WV, USA
- PCV28** B6 pgA134 **VOLUME AND STRUCTURE OF ANTIHYPERTENSIVE DRUGS CONSUMPTION IN UKRAINE**  
**Iakovlieva L**, Mishchenko O, Bezditko N, Gerasymova O, Kyrychenko O, Tkachova O, Matyashova N, National University of Pharmacy, Kharkiv, Ukraine
- PCV29** B7 pgA134 **OUTCOMES, HEALTH COSTS AND USE OF STATINS IN 6,226 PATIENTS ADMITTED IN 2011 FOR AN ACUTE CORONARY SYNDROME (ACS) OCCURRING IN A LARGE COMMUNITY SETTING OF 2,989,512 SUBJECTS**  
**Maggioni AP<sup>1</sup>**, Cinconze E<sup>2</sup>, Rossi E<sup>2</sup>, De Rosa M<sup>2</sup>, Esposito I<sup>3</sup>, Martini N<sup>3</sup>, <sup>1</sup>ANMCO Research Center, Florence, Italy, <sup>2</sup>CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, <sup>3</sup>Accademia Nazionale di Medicina, Roma, Italy
- PCV30** B8 pgA134 **PHYSICIAN'S ADHERENCE TO TREATMENT GUIDELINES IN DEEP VEIN THROMBOSIS AT AN INDIAN TERTIARY HEALTHCARE FACILITY**  
**Tiwari P<sup>1</sup>**, Sunarikani R<sup>1</sup>, Malhotra S<sup>2</sup>, <sup>1</sup>NIPER MOHALI INDIA, MOHALI, India, <sup>2</sup>Private Hospital, MOHALI, India
- PCV31** B9 pgA135 **TRENDS IN ANTIHYPERTENSIVE MEDICATION USE IN US OFFICE-BASED PRACTICES: ARE ELDERLY**

## PATIENTS TREATED DIFFERENTLY?

**Gu A**<sup>1</sup>, Yue Y<sup>2</sup>, Argulian E<sup>3</sup>,<sup>1</sup>St. John's University, Jamaica, NY, USA, <sup>2</sup>Baruch College/CUNY, New York, NY, USA, <sup>3</sup>Mount Sinai St. Luke's Hospital, New York, NY, USA

- PCV32 B10 pgA135 COMPARISON OF DIFFERENT METABOLIC SYNDROME CRITERIA AND INDIVIDUAL RISK FACTORS IN THE RISK PREDICTION OF CARDIOVASCULAR AND CHRONIC DISEASES**  
**Bhounsule P**, Peterson AM, University of the Sciences in Philadelphia, Philadelphia, PA, USA
- PCV33 B11 pgA135 HYPERKALEMIA IS HIGHLY PREVALENT IN PATIENTS WITH CARDIORENAL COMORBIDITIES COMPARED TO PATIENTS WITHOUT THESE COMORBIDITIES**  
Latts LM<sup>1</sup>, Reaven NL<sup>2</sup>, Funk SE<sup>2</sup>, McGaughey KJ<sup>3</sup>, **Adamson RT**<sup>4</sup>,<sup>1</sup>LML Health Solutions LLC, Denver, CO, USA, <sup>2</sup>Strategic Health Resources, La Canada, CA, USA, <sup>3</sup>California Polytechnic State University, San Luis Obispo, CA, USA, <sup>4</sup>Barnabas Health, West Orange, NJ, USA
- PCV34 B12 pgA135 VENOUS THROMBOEMBOLISM PREVALENCE IN FRENCH AND US HOSPITALS: COMPARISON ON THE BASIS OF THE NATIONAL DATA BASES**  
**Allaert F**<sup>1</sup>, Quantin C<sup>2</sup>, Benzenine M<sup>2</sup>,<sup>1</sup>Medical evaluation Chair ESC Dijon, Dijon, France, <sup>2</sup>university hospital Dijon, Dijon, France
- PCV35 B13 pgA135 THE PREVALENCE AND ODDS-RATIOS OF SELF-REPORTED DIAGNOSIS OF HYPERTENSION AMONG US ADULTS BY RACIAL/ETHNIC SUBGROUPS, EXAMINING THE JOINT EFFECT OF MULTIPLE RISK FACTORS: NATIONAL HEALTH INTERVIEW SURVEY, 2004 - 2013**  
**Godwin O**, Brown LM, Chapman University, Irvine, CA, USA
- PCV36 B14 pgA135 GEOGRAPHIC DIFFERENCES IN AVAILABILITY OF ANTIHYPERTENSIVE MEDICATIONS: A COMPARISON OF AUSTRALIA, CANADA, SAUDI ARABIA, UK, AND THE US**  
**Almutairi H**<sup>1</sup>, Alzarea AI<sup>1</sup>, Seoane-Vazquez E<sup>1</sup>, Mekary R<sup>2</sup>,<sup>1</sup>MCPHS University, Boston, MA, USA, <sup>2</sup>MCPHS University, N/A, MA, USA
- PCV37 B15 pgA136 A RETROSPECTIVE DATABASE STUDY TO INVESTIGATE THE MORBIDITY AND PHARMACEUTICAL INTERVENTION OF PULMONARY ARTERIAL HYPERTENSION IN JAPAN**  
**Sawachi S**, Pfizer Japan Inc., Tokyo, Japan
- PCV38 B16 pgA136 INCREASED RISK OF ARRHYTHMIA IN PATIENTS WITH PSORIASIS: A MATCHED COHORT STUDY**  
**Chang W**<sup>1</sup>, Chiu H<sup>2</sup>, Huang W<sup>1</sup>, Wen Y<sup>3</sup>, Tsai Y<sup>1</sup>, Tsai T<sup>2</sup>,<sup>1</sup>National Yang Ming University, Taipei, Taiwan, <sup>2</sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>3</sup>Chang Gung University, Taoyuan, Taiwan
- PCV39 B17 pgA136 LIFE'S SIMPLE 7 AND CARDIOVASCULAR DISEASE RISK KNOWLEDGE IN HONG KONG**  
**Lee V**, Kong KY, Fong F, Ngai L, Wong V, Yan BP, Chinese University of Hong Kong, Shatin, Hong Kong
- PCV40 B18 pgA136 FACTORS THAT NEGATIVELY INFLUENCE THE PREDICTION OF WARFARIN STABLE DOSE WHEN EMPLOYING A GENOTYPE-GUIDED APPROACH**  
**Lee W**<sup>1</sup>, Chumnumwat S<sup>1</sup>, Duarte J<sup>1</sup>, Gratie D<sup>1</sup>, Galanter WL<sup>1</sup>, Walton SM<sup>1</sup>, Krishnan JA<sup>1</sup>, Bauman JL<sup>1</sup>, Cavallari LH<sup>2</sup>, Nutescu EA<sup>1</sup>,<sup>1</sup>University of Illinois at Chicago, Chicago, IL, USA, <sup>2</sup>University of Florida, Gainesville, FL, USA
- PCV41 B19 pgA136 EXAMINING ASSOCIATION BETWEEN LIVER ENZYMES AND LIPID LEVELS AMONGST ADULTS IN THE UNITED STATES: A CROSS SECTIONAL STUDY**  
**Sakharkar P**, Deb S, Roosevelt University College of Pharmacy, Schaumburg, IL, USA
- PCV42 B20 pgA137 STATIN USE AND RISK OF DEVELOPING DIABETES: A NETWORK META-ANALYSIS**  
Thakker D, **Nair SR**, Jamdade V, Shaikh S, Pagada A, Oomman S, Malik A, Capita Ind Pvt. Ltd., Mumbai, India
- PCV43 B21 pgA137 COSTS AND OUTCOMES OF PATIENTS ADMITTED FOR A CARDIOVASCULAR ISCHEMIC DISEASE IN A LARGE COMMUNITY SETTING OF 2,989,512 SUBJECTS OF THE ITALIAN NATIONAL HEALTH SERVICE (NHS)**  
**Maggioni AP**<sup>1</sup>, Cinconze E<sup>2</sup>, Rossi E<sup>2</sup>, De Rosa M<sup>2</sup>, Esposito I<sup>3</sup>, Martini N<sup>3</sup>,<sup>1</sup>ANMCO Research Center, Florence, Italy, <sup>2</sup>CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, <sup>3</sup>Accademia Nazionale di Medicina, Roma, Italy
- PCV44 C1 pgA137 ASSESSMENT OF DRUG UTILIZATION PATTERN AND CLINICAL OUTCOME IN PREGNANCY INDUCED HYPERTENSION IN TERTIARY CARE HOSPITAL**  
**Bandari mM**, kakatiya university, warangal, India

---

## CARDIOVASCULAR DISORDERS - Cost Studies

- PCV45 C2 pgA137 ESTIMATING THE BUDGET IMPACT OF CLEVIDIPINE FOR THE MANAGEMENT OF PERIOPERATIVE BLOOD PRESSURE IN CARDIAC SURGERY: A US PERSPECTIVE**  
**Baker TM**<sup>1</sup>, Kuan R<sup>2</sup>, Crothers TA<sup>3</sup>, Wang Y<sup>3</sup>,<sup>1</sup>ICON Plc, Morristown, NJ, USA, <sup>2</sup>Independent, Portland, OR, USA, <sup>3</sup>The Medicines Company, Parsippany, NJ, USA
- PCV46 C3 pgA137 ECONOMIC IMPLICATIONS OF INCREASED UTILIZATION OF 5% ALBUMIN FOR FLUID RESUSCITATION POST ON-PUMP CARDIAC PROCEDURES IN US HOSPITALS**  
**Runken MC**<sup>1</sup>, Khangulov VS<sup>2</sup>, Munson SH<sup>2</sup>, Peyerl FW<sup>2</sup>, Bunke M<sup>1</sup>,<sup>1</sup>Grifols, Inc., Research Triangle Park, NC, USA, <sup>2</sup>Boston Strategic Partners, Inc., Boston, MA, USA
- PCV47 C4 pgA137 EXPECTED COST OF DRUG THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION, DIABETES**



## MELLITUS AND DYSLIPIDEMIA IN CHILE: A PROBABILISTIC ANALYSIS

**Balmaceda C**<sup>1</sup>, Espinoza MA<sup>2</sup>,<sup>1</sup>Instituto de Salud Pública, Santiago, Chile, <sup>2</sup>Pontificia Universidad Católica de Chile, Santiago, Chile

- PCV48 C5 pgA138 COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF CONCOR® AM VERSUS BISOPROLOL PLUS AMLODIPINE IN SYSTEMIC ARTERIAL HYPERTENSION TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM**  
**Fujii RK**<sup>1</sup>, Restrepo M<sup>2</sup>, Fernandes RA<sup>3</sup>, Haas L<sup>4</sup>, Pepe C<sup>3</sup>, Junqueira M<sup>1</sup>,<sup>1</sup>Merck Serono, São Paulo, Brazil, <sup>2</sup>Merck Serono, Bogota, Colombia, <sup>3</sup>Grupo Resulta, São Paulo, Brazil, <sup>4</sup>ANOVA, Rio de Janeiro, Brazil
- PCV49 C6 pgA138 ESTIMATED SAVINGS IN MEDICAL COSTS WHEN NEW ORAL ANTICOAGULANTS ARE USED FOR THE TREATMENT OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM VS. WARFARIN IN THE U.S**  
**Amin A**<sup>1</sup>, Bruno A<sup>2</sup>, Trocio J<sup>3</sup>, Lin J<sup>4</sup>, Lingohr-Smith M<sup>4</sup>,<sup>1</sup>University of California, Irvine, CA, USA, <sup>2</sup>Bristol-Myers Squibb, Plainsboro, NJ, USA, <sup>3</sup>Pfizer, New York, NY, USA, <sup>4</sup>Novosys Health, Green Brook, NJ, USA
- PCV50 C7 pgA138 A RETROSPECTIVE ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION AND THE ECONOMIC BURDEN AMONG U.S. LONG-TERM CARE FACILITY PATIENTS DIAGNOSED WITH STROKE**  
Huang A<sup>1</sup>, Shrestha S<sup>1</sup>, Baser O<sup>2</sup>, Yuce H<sup>3</sup>, **Wang L**<sup>1</sup>,<sup>1</sup>STATinMED Research, Plano, TX, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, <sup>3</sup>City University of New York & STATinMED Research, New York, NY, USA
- PCV51 C8 pgA138 MEDICATION COST IMPLICATION FOR THE MANAGEMENT OF HYPERTENSION AND DIABETES IN NIGER DELTA: TERTIARY HOSPITAL BASED STUDY IN BAYELSA STATE, NIGERIA**  
**Ganiyu KA**<sup>1</sup>, Erah PO<sup>2</sup>,<sup>1</sup>Niger Delta University, Wilberforce Island, Bayelsa State, Nigeria, <sup>2</sup>University of Benin, Benin City, Nigeria
- PCV52 C9 pgA138 ESTIMATING THE COST OF ILLNESS OF GIANT CELL ARTERITIS**  
**Babigumira JB**<sup>1</sup>, Li M<sup>1</sup>, Boudreau DM<sup>1</sup>, Best JH<sup>2</sup>, Garrison LP<sup>1</sup>,<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Genentech, Inc, South San Francisco, CA, USA
- PCV53 C10 pgA138 ACUTE, SHORT-TERM AND LONG-TERM COSTS OF CARDIOVASCULAR EVENTS AMONG HYPERLIPIDEMIA PATIENTS**  
**Paoli CJ**<sup>1</sup>, Gandra SR<sup>1</sup>, Henk HJ<sup>2</sup>,<sup>1</sup>Amgen, Inc., Thousand Oaks, CA, USA, <sup>2</sup>Optum, Eden Prairie, MN, USA
- PCV54 C11 pgA139 TREATMENT EFFECTS ON THE COST BURDEN OF HOSPITALIZATIONS IN PATIENTS WITH CHRONIC SYSTOLIC HEART FAILURE**  
**Kansal A**<sup>1</sup>, Kielhorn A<sup>2</sup>, Dorman E<sup>1</sup>, Krotneva S<sup>3</sup>, Zheng Y<sup>1</sup>, Patel H<sup>2</sup>, Borer J<sup>4</sup>,<sup>1</sup>Evidera, Bethesda, MD, USA, <sup>2</sup>Amgen, Thousand Oaks, CA, USA, <sup>3</sup>Evidera, St-Laurent, QC, Canada, <sup>4</sup>State University of New York Downstate Medical Center, Brooklyn and New York, NY, USA
- PCV55 C12 pgA139 DIRECT MEDICAL BURDEN AND READMISSION RATES AMONG NON-ELDERLY PATIENTS WITH ACUTE ISCHEMIC STROKE IN THE UNITED STATES**  
Johnson BH<sup>1</sup>, Bonafede MM<sup>1</sup>, **Watson C**<sup>2</sup>,<sup>1</sup>Truven Health Analytics, Cambridge, MA, USA, <sup>2</sup>Biogen Idec, Cambridge, MA, USA
- PCV56 C13 pgA139 INCREMENTAL COSTS OF GIANT CELL ARTERITIS IN FRANCE**  
**Costa N**<sup>1</sup>, Pugnet G<sup>2</sup>, Bouscaren N<sup>1</sup>, Bourrel R<sup>3</sup>, Lapyere-Mestre M<sup>4</sup>, Sailer L<sup>2</sup>, Molinier L<sup>1</sup>,<sup>1</sup>Univeristy Hospital of Toulouse, Toulouse, France, <sup>2</sup>University of Toulouse III, Toulouse, France, <sup>3</sup>Regional Health Insurance, Toulouse, France, <sup>4</sup>INSERM UMR 1027, Toulouse, France
- PCV57 C14 pgA139 SYSTEMATIC REVIEW OF THE SOCIETAL COST AND ECONOMIC BURDEN ASSOCIATED WITH CHRONIC HEART FAILURE**  
**Allen F**<sup>1</sup>, Haroun R<sup>1</sup>, King D<sup>2</sup>,<sup>1</sup>Novartis Pharmaceuticals UK Limited, Surrey, UK, <sup>2</sup>Abacus International, Bicester, UK
- PCV58 C15 pgA139 LONG-TERM ECONOMIC BURDEN ASSOCIATED WITH CARDIOVASCULAR EVENTS AMONG HIGH-RISK PATIENTS WITH HYPERLIPIDEMIA**  
Fox KM<sup>1</sup>, Wang L<sup>2</sup>, Gandra SR<sup>3</sup>, **Quek RG**<sup>3</sup>, Li L<sup>2</sup>, Baser O<sup>4</sup>,<sup>1</sup>Strategic Healthcare Solutions, LLC, Monkton, MD, USA, <sup>2</sup>STATinMED Research, Plano, TX, USA, <sup>3</sup>Amgen, Inc., Thousand Oaks, CA, USA, <sup>4</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA
- PCV59 C16 pgA140 THE INCREMENTAL COST OF REOPERATIONS FOR BLEEDING EVENTS IN CARDIAC AND VASCULAR RECONSTRUCTIVE SURGERY**  
Gunnarsson C<sup>1</sup>, **Lim S**<sup>2</sup>, David G<sup>3</sup>, Riebman JB<sup>2</sup>, Martin L<sup>4</sup>, Kocharian R<sup>2</sup>,<sup>1</sup>CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, <sup>2</sup>Ethicon, Inc., Somerville, NJ, USA, <sup>3</sup>The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, <sup>4</sup>Johnson & Johnson Medical Products, Markham, ON, Canada
- PCV60 D1 pgA140 COST EFFECTIVENESS OF STATINS IN PRIMARY PREVENTION OF CORONARY HEART DISEASE: A SYSTEMATIC REVIEW AND QUALITY ASSESSMENT OF ECONOMIC EVIDENCE TO ELUCIDATE RECENT TRENDS IN USA**  
**Bardia A**<sup>1</sup>, Garg G<sup>2</sup>,<sup>1</sup>Invaluesys Research, Hyderabad, India, <sup>2</sup>Invaluesys Research, Burgdorf, Germany
- PCV62 D2 pgA140 ANNUAL MEDICATION COST ATTRIBUTED TO EACH KIND OF TREATMENT OF PATIENTS SUBJECTED TO CRMS IMPLANTATION**

**Fanourgiakis JA**<sup>1</sup>, Simantirakis E<sup>2</sup>, Kanoupakis E<sup>2</sup>, Chrysostomakis S<sup>2</sup>, Maniadakis N<sup>3</sup>, Kourlamba G<sup>3</sup>, Vardas P<sup>2,1</sup>, Department of Cardiology, Heraklion University Hospital, Crete, Greece. Department of Accounting and Finance, School of Economics and Management, T.E.I. Heraklion, Crete, Greece. Department of Business Administration, T.E.I. Agios Nikolaos, Crete, Greece, Heraklion, Greece, <sup>2</sup>Department of Cardiology, Heraklion University Hospital, Heraklion, Greece, <sup>3</sup>Department of Health Services Management, National School of Public Health, Athens, Greece, Athens, Greece

- PCV63 D3 pgA140 COST-EFFECTIVENESS OF STRATEGIES FOR MANAGEMENT OF DEEP VEIN THROMBOSIS**  
**Kostyuk A**<sup>1</sup>, Akanov A<sup>2</sup>, Almadiyeva A<sup>2,1</sup>, Kazakh Medical University for Continuing Education, Astana, Kazakhstan, <sup>2</sup>Astana Medical University, Astana, Kazakhstan
- PCV64 D4 pgA140 ECONOMIC EVALUATION OF DABIGATRAN ETEXILATE FOR THE TREATMENT OF DEEP VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM**  
**Huicochea-Bartelt JL**<sup>1</sup>, Ortiz-Blas LA<sup>2</sup>, Herran S<sup>1</sup>, Gay-Molina J<sup>2</sup>, Robledo JL<sup>1,1</sup>, Boehringer Ingelheim, Distrito Federal, Mexico, <sup>2</sup>Tecnología e Informática para la Salud, Distrito Federal, Mexico
- PCV65 D5 pgA140 COST-EFFECTIVENESS OF DABIGATRAN IN NON VALVULAR ATRIAL FIBRILLATION IN COLOMBIA**  
Triana JJ<sup>1</sup>, **Castañeda-Cardona C**<sup>2</sup>, Parada L<sup>3</sup>, Rosselli D<sup>1,1</sup>, Pontificia Universidad Javeriana, Bogota, Colombia, <sup>2</sup>Pontificia Universidad Javeriana, Bogotá, Colombia, <sup>3</sup>Boehringer Ingelheim, Bogota, Colombia
- PCV66 D6 pgA141 ECONOMIC EVALUATION OF DABIGATRAN ETEXILATE VERSUS WARFARIN, RIVAROXABAN AND APIXABAN IN STROKE PREVENTION IN ATRIAL FIBRILLATION**  
**Huicochea-Bartelt JL**<sup>1</sup>, Gay-Molina J<sup>2</sup>, Ortiz-Blas LA<sup>2</sup>, Herran S<sup>1,1</sup>, Boehringer Ingelheim, Distrito Federal, Mexico, <sup>2</sup>Tecnología e Informática para la Salud, Distrito Federal, Mexico
- PCV67 D7 pgA141 COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN ATORVASTATIN AND ATORVASTATIN-EZETIMIBE COMBINATION AMONG PATIENTS WITH DIABETES MELLITUS OR CARDIOVASCULAR DISEASE IN GENERAL PRACTICE**  
**Rattanakunooprakarn H**<sup>1</sup>, Tewthanom K<sup>1</sup>, Sakthong P<sup>2,1</sup>, Silapakorn University, Meaung, Thailand, <sup>2</sup>Chulalongkorn University, Phatumwan, Thailand
- PCV68 D8 pgA141 CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS WITH ATHEROTHROMBOSIS: A CAPRIE-BASED ECONOMIC ANALYSIS IN A HEALTH RESOURCE LIMITED SETTING**  
Li T<sup>1</sup>, Liu MB<sup>2</sup>, Ben H<sup>3</sup>, Xu ZX<sup>4</sup>, Zhong H<sup>5</sup>, **Wu B**<sup>5,1</sup>, Department of Pharmacy, Yuxi People's Hospital, Yuxi, China, <sup>2</sup>Department of Pharmacy, Fujian Union Hospital, Fujian, China, <sup>3</sup>Department of Cardiology, Ren Ji Hospital, Shanghai, China, <sup>4</sup>Department of Cardiology, Gongli Hospital, Shanghai, China, <sup>5</sup>Department of General Surgery, Ren Ji Hospital, Shanghai, China
- PCV69 D9 pgA141 COST-EFFECTIVENESS OF RIOCIQUAT FOR TREATMENT OF PATIENTS WITH INOPERABLE OR POST-OPERATIVE RECURRENT/PERSISTENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN TURKEY**  
Erdal E<sup>1</sup>, Ozdemir O<sup>2</sup>, Yildizeli B<sup>3</sup>, Kaymaz C<sup>4</sup>, Okumus G<sup>5</sup>, Mogulkoc N<sup>6</sup>, Nalbantgil S<sup>6</sup>, **Deger C**<sup>7</sup>, Sumer F<sup>7</sup>, Parali E<sup>1</sup>, Tunalioğlu A<sup>1</sup>, Sar C<sup>1</sup>, Asan S<sup>1</sup>, Ozel O<sup>1,1</sup>, Bayer Turk Kimya San. Ltd. Sti, Istanbul, Turkey, <sup>2</sup>Yorum Consultancy, Istanbul, Turkey, <sup>3</sup>Marmara University Faculty of Medicine, Istanbul, Turkey, <sup>4</sup>Kosuyolu Training and Research Hospital, Istanbul, Turkey, <sup>5</sup>Istanbul University Faculty of Medicine, Istanbul, Turkey, <sup>6</sup>Ege University Faculty of Medicine, Izmir, Turkey, <sup>7</sup>Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey
- PCV70 D10 pgA141 COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF CATHETER DIRECTED THROMBOLYSIS WITH UROKINASE AND ALTEPLASE FOR TREATMENT OF ACUTE PERIPHERAL ARTERY DISEASE**  
**Kostyuk A**<sup>1</sup>, Akanov A<sup>2</sup>, Almadiyeva A<sup>2,1</sup>, Kazakh Medical University for Continuing Education, Astana, Kazakhstan, <sup>2</sup>Astana Medical University, Astana, Kazakhstan
- PCV72 D11 pgA142 COST EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO ORAL ANTICOAGULANTS IN THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN GUATEMALA IN 2014**  
**Garita-Aguilar M**<sup>1</sup>, Peralta-Acon M<sup>1</sup>, Jiménez-Crespo L<sup>2,1</sup>, Pfizer Central America and Caribbean, San José, Costa Rica, <sup>2</sup>Instituto Guatemalteco del Seguro Social, Ciudad de Guatemala, Guatemala
- PCV73 D12 pgA142 COST EFFECTIVENESS OF APIXABAN FOR STROKE PREVENTION IN NON VALVULAR ATRIAL FIBRILLATION IN THE ECUATORIAN PUBLIC HEALTHCARE SECTOR**  
Rosado-Buzzo A<sup>1</sup>, Albuja M<sup>2</sup>, Garcia-Molliendo L<sup>3</sup>, **Luna-Casas G**<sup>3,1</sup>, Linkd and Links, Mexico City, Mexico, <sup>2</sup>Pfizer Ecuador, Quito, Mexico, <sup>3</sup>Links and Links, Mexico City, Mexico
- PCV74 D13 pgA142 COST-EFFECTIVENESS ANALYSIS AMONG PATIENTS WITH DIABETES MELLITUS OR CARDIOVASCULAR DISEASE RECEIVING SECOND-LINE TREATMENT WITH INTENSIVE DOSES OF SIMVASTATIN ATORVASTATIN AND ATORVASTATIN-EZETIMIBE COMBINATION IN GENERAL PRACTICE**  
**Tewthanom K**<sup>1</sup>, Rattanakunooprakarn H<sup>1</sup>, Sakthong P<sup>2,1</sup>, Silapakorn University, Meaung, Thailand, <sup>2</sup>Chulalongkorn University, Phatumwan, Thailand
- PCV76 D14 pgA142 SYSTEMATIC REVIEW OF RECENT PHARMACOECONOMIC EVALUATIONS RELATED TO GENOTYPE-GUIDED THERAPY IN PATIENTS AT HIGH RISK FOR THROMBOTIC EVENT**  
**Smith SA**, University of Texas at Austin, Austin, TX, USA
- PCV77 D15 pgA142 COST EFFECTIVENESS OF AN ANTICOAGULANT CLINIC AFTER INTRODUCTION OF NOACS FOR STROKE PREVENTION IN ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES**

Alhazami M<sup>1</sup>, Holdford DA<sup>2</sup>,<sup>1</sup>virginia commonwealth university, glen allen, VA, USA, <sup>2</sup>virginia commonwealth university, richmond, VA, USA

- PCV78 D16 pgA142 **THE COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED WITH EDOXABAN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN THE UK**  
Jugrin AV<sup>1</sup>, Ustyugova AV<sup>2</sup>, Lamotte M<sup>1</sup>, Sunderland TJ<sup>3</sup>,<sup>1</sup>IMS Health HEOR, Vilvoorde, Belgium, <sup>2</sup>Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, <sup>3</sup>Boehringer Ingelheim, Berkshire, UK
- PCV79 E1 pgA143 **DOES AZILSARTAN MEDOXIMIL – CHLOROTHALIDONE LOWER RISK OF CORONARY HEART DISEASE THAN OLMESARTAN MEDOXIMIL – HYDROCHLORTHIAZIDE IN PATIENTS WITH ESSENTIAL HYPERTENSION: A COST-EFFECTIVE ANALYSIS**  
Bhansali A<sup>1</sup>, Sangsiry SS<sup>2</sup>,<sup>1</sup>University of Houston College of Pharmacy, Houston, TX, USA, <sup>2</sup>University of Houston, Houston, TX, USA
- PCV80 E2 pgA143 **COST-MINIMIZATION ANALYSIS OF TINZAPARIN SODIUM COMPARED TO OTHER LOW-MOLECULAR-WEIGHT HEPARINS FOR PATIENTS WITH DEEP VENOUS THROMBOSIS**  
Diaz JP<sup>1</sup>, Soto Molina H<sup>2</sup>, Marquez M<sup>3</sup>, Escobar Juárez Y<sup>2</sup>,<sup>1</sup>Universidad Nacional Autonoma de Mexico, México D.F., Mexico, <sup>2</sup>HS Estudios Farmacoeconómicos, Mexico City, Mexico, <sup>3</sup>Universidad Autonoma Metropolitana, México D.F., Mexico
- PCV81 E3 pgA143 **COST-UTILITY ANALYSIS OF APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION (AF) AT THE PERUVIAN SOCIAL SECURITY (ESSALUD)**  
Sanabria C<sup>1</sup>, Cabrejos J<sup>1</sup>, Garrido Lecca S<sup>2</sup>, Olortegui A<sup>3</sup>, Guevara C<sup>3</sup>,<sup>1</sup>Universidad Nacional Mayor de San Marcos, Lima, Peru, <sup>2</sup>Bristol-Myers Squibb, Lima, Peru, <sup>3</sup>Instituto Nacional Cardiovascular (INCOR), Lima, Peru
- PCV82 E4 pgA143 **COST EFFECTIVENESS OF DRUGS FOR PULMONARY ARTERIAL HYPERTENSION: A CANADIAN STUDY**  
Coyle K<sup>1</sup>, Coyle D<sup>2</sup>, Jabr M<sup>3</sup>, Blouin J<sup>3</sup>, Lee K<sup>3</sup>,<sup>1</sup>Brunel University, Uxbridge, UK, <sup>2</sup>University of Ottawa, Ottawa, ON, Canada, <sup>3</sup>CADTH, Ottawa, ON, Canada
- PCV83 E5 pgA143 **REAL-WORLD OUTCOMES OF ACUTE ISCHEMIC STROKE PATIENTS IN THE MEDICARE POPULATION**  
Watson C<sup>1</sup>, Burudpakdee C<sup>2</sup>, Noone J<sup>2</sup>, Seetasith A<sup>3</sup>, Nyandegge A<sup>3</sup>,<sup>1</sup>Biogen Idec, Cambridge, MA, USA, <sup>2</sup>University of North Carolina at Charlotte, Charlotte, NC, USA, <sup>3</sup>Market Access Solutions LLC, Raritan, NJ, USA
- PCV84 E6 pgA144 **THE TOTAL DIRECT HEALTHCARE COST OF AORTIC AND MITRAL VALVULAR DISEASE: EVIDENCE FROM US NATIONAL SURVEY DATA**  
Rizzo JA<sup>1</sup>, Chen J<sup>2</sup>, Mallow PJ<sup>3</sup>, Moore M<sup>4</sup>,<sup>1</sup>Stony Brook University, Stony Brook, NY, USA, <sup>2</sup>University of Maryland, College Park, NY, USA, <sup>3</sup>CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, <sup>4</sup>Edwards Lifesciences, Inc., Irvine, CA, USA

---

#### CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PCV85 E7 pgA144 **PERSISTENCE AND COMPLIANCE WITH LIPID- LOWERING DRUGS IN PATIENTS WITH CHRONIC KIDNEY DISEASE**  
Truong VT, Moisan J, Kröger E, Langlois S, Gregoire J,Laval University, Quebec, QC, Canada
- PCV86 E8 pgA144 **INERTIA OR ACTUAL SWITCHING ON MEDICATION ADHERENCE AND ECONOMIC WELL-BEING OF MEDICARE BENEFICIARIES ENROLLED IN PART D PLANS**  
Basu R, Baylor Scott & White Health, Temple, TX, USA
- PCV87 E9 pgA144 **COMPLIANCE AND CONTROL OF HYPERTENSION WITH CO-MORBIDITIES IN PRIMARY CARE IN UKRAINE**  
Korzh O,Kharkov Medical Academy of Postgraduate Education, Kharkov, Ukraine
- PCV88 E10 pgA144 **COMPARING THE EQ-5D-3L AND SF-6D UTILITY SCORES OF ACUTE CORONARY SYNDROME PATIENTS FROM AN ASIAN POPULATION**  
Azmi S<sup>1</sup>, Anchah L<sup>2</sup>, Goh A<sup>1</sup>, Fong A<sup>3</sup>,<sup>1</sup>Azmi Burhani Consulting, Petaling Jaya, Malaysia, <sup>2</sup>Sarawak General Hospital Heart Centre, Kuching, Malaysia, <sup>3</sup>Sarawak General Hospital, Kuching, Malaysia
- PCV89 E11 pgA144 **HEALTH UTILITIES OF HYPERTENSIVE PATIENTS IN VIETNAM**  
Nguyen TP, C.C.M. S, Postma MJ,Groningen University, Groningen, The Netherlands
- PCV90 E12 pgA145 **DETERMINANTS OF UTILITY BASED ON THE EQ-5D IN CHRONIC HEART FAILURE PATIENTS AND THEIR CHANGE OVER TIME: RESULTS FROM THE SWEDISH HEART FAILURE REGISTRY**  
Berg J<sup>1</sup>, Lindgren P<sup>2</sup>, Mejhert M<sup>3</sup>, Edner M<sup>4</sup>, Dahlström U<sup>5</sup>, Kahan T<sup>6</sup>,<sup>1</sup>Mapi, Stockholm, Sweden, <sup>2</sup>IVBAR, Stockholm, Sweden, <sup>3</sup>Ersta Hospital, Stockholm, Sweden, <sup>4</sup>Karolinska Institutet, Stockholm, Sweden, <sup>5</sup>Linköping University, Linköping, Sweden, <sup>6</sup>Danderyd Hospital, Stockholm, Sweden
- PCV91 E13 pgA145 **VALIDATION OF A SYNDROME-SPECIFIC INSTRUMENT TO ASSESS ANGINA TREATED BY TRADITIONAL CHINESE MEDICINE (TCM-SAQ): THE ABILITY TO DETECT CHANGE**  
Zhang HY, Yu L, Lv MJ, Chen ZH, Yang GL,Liaoning University of Traditional Chinese Medicine, Shenyang, China
- PCV92 E14 pgA145 **TRAJECTORIES OF ANGINA HEALTH-RELATED QUALITY OF LIFE AFTER ACUTE CORONARY SYNDROME IN TRACE-CORE**  
Nobel L<sup>1</sup>, Tjia J<sup>2</sup>, Saczynski JS<sup>1</sup>, Waring ME<sup>1</sup>, Anatchkova MD<sup>1</sup>, Ware J<sup>1</sup>, Ash AS<sup>1</sup>, Kiefe CI<sup>1</sup>, Allison JJ<sup>1</sup>,<sup>1</sup>University of Massachusetts Medical School, WORCESTER, MA, USA, <sup>2</sup>University of Massachusetts Medical

**CARDIOVASCULAR DISORDERS - Health Care Use & Policy Studies**

- PCV93 E15 pgA145 IMPLEMENTATION OF THE AMERICAN DIABETES ASSOCIATION'S STANDARDS OF MEDICAL CARE: THE CASE OF STATIN UTILIZATION IN THE ELDERLY WITH DIABETES**  
**Li M**, Lu K, Maxwell WD, Schulz RM, University of South Carolina, Columbia, SC, USA
- PCV94 E16 pgA145 PATIENTS IN THE WAITING LIST OF BARIATRIC SURGERY IN THE BRAZILIAN PUBLIC SECTOR TREATMENT PATTERNS AND HEALTH OUTCOMES: A NON-INTERVENTIONAL SINGLE-SITE RETROSPECTIVE STUDY**  
Junqueira Junior SM<sup>1</sup>, Luque A<sup>1</sup>, Cabra HA<sup>2</sup>, **Andrade PC**<sup>1</sup>, Oliveira FM<sup>3</sup>, Brasil N<sup>1</sup>, Rasesra I<sup>4</sup>,<sup>1</sup>Johnson&Johnson Medical Brazil, Sao Paulo, Brazil, <sup>2</sup>Johnson & Johnson Medical, Mexico, D.F., Mexico, <sup>3</sup>Johnson & Johnson Medical Brazil, São Paulo, Brazil, <sup>4</sup>Clinica Bariátrica, São Paulo, Brazil
- PCV95 F1 pgA146 A CONSERVATIVE APPROACH TO ASSESS WARFARIN TIME-IN-THERAPEUTIC RANGES AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN AN INTEGRATED HEALTHCARE DELIVERY SYSTEM SETTING IN THE U.S**  
**Deitelzweig S**<sup>1</sup>, Evans M<sup>2</sup>, Hillson E<sup>3</sup>, Trocio J<sup>4</sup>, Bruno A<sup>3</sup>, Tan W<sup>4</sup>, Lingohr-Smith M<sup>5</sup>, Lin J<sup>5</sup>,<sup>1</sup>Ochsner Medical Center, New Orleans, LA, USA, <sup>2</sup>Geisinger Health System, Danville, PA, USA, <sup>3</sup>Bristol-Myers Squibb, Plainsboro, NJ, USA, <sup>4</sup>Pfizer, New York, NY, USA, <sup>5</sup>Novosys Health, Green Brook, NJ, USA
- PCV96 F2 pgA146 ANALYSIS OF KENTUCKY MEDICAID MANAGED CARE VERSUS FEE-FOR-SERVICE SYSTEMS: MEDICATION ADHERENCE IN PATIENTS WITH ESSENTIAL HYPERTENSION**  
**Herren C**, Brouwer E, Talbert J, University of Kentucky College of Pharmacy, Lexington, KY, USA
- PCV97 F3 pgA146 THE 5 PRINCIPAL CAUSES OF DEATH IN MEXICO IN THE LAST 5 YEARS, IS THE PUBLIC HEALTH SYSTEM COVERING THESE NEEDS?**  
**Lemus F**<sup>1</sup>, Rivas R<sup>2</sup>,<sup>1</sup>National Institute of Public Health, Estado de México, Mexico, <sup>2</sup>National Institute of Public Health, Naucalpan de Juarez, Mexico
- PCV98 F4 pgA146 SOCIOECONOMIC FACTORS AND PRESCRIBED MEDICINES EXPENDITURES ASSOCIATED WITH ANTIHYPERLIPIDEMIC THERAPY; A COMPARISON BETWEEN HYPERLIPIDEMIA PATIENTS WITH AND WITHOUT TREATMENT**  
**Althemery AU**, Alfaifi A, Lai L, Nova Southeastern University, Davie, FL, USA
- PCV99 F5 pgA146 THE USE OF STATINS AMONG PRIOR-USERS AFTER HEMODIALYSIS**  
**Shih Y**<sup>1</sup>, Liu Y<sup>1</sup>, Huang W<sup>1</sup>, Wen Y<sup>2</sup>, Tsai Y<sup>1</sup>,<sup>1</sup>National Yang Ming University, Taipei, Taiwan, <sup>2</sup>Chang Gung University, Taoyuan, Taiwan
- PCV100 F6 pgA146 AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM USAGE IN CROATIA DURING THE FOURTEEN-YEAR PERIOD: IMPACT OF GENERICS**  
**Vitezic D**<sup>1</sup>, Kucan M<sup>2</sup>, Mrcic Pelcic J<sup>3</sup>, Vitezic M<sup>4</sup>,<sup>1</sup>University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, <sup>2</sup>JGL dd, Rijeka, Rijeka, Croatia, <sup>3</sup>University of Rijeka Medical School, Rijeka, Croatia, <sup>4</sup>University Orthopaedic Clinic Lovran and University of Rijeka Medical School, Lovran, Croatia
- PCV101 F7 pgA147 RESULTS OF AN INTERVENTION IN PRESCRIPTION OF CONVENTIONAL RELEASE VERAPAMIL IN PATIENTS WITH HYPERTENSION IN COLOMBIA**  
**Machado J**, Machado-Duque M, Giraldo C, Universidad Tecnológica de Pereira, Pereira, Colombia
- PCV102 F8 pgA147 DRUG USE AMONG SENIORS ON PUBLIC DRUG PROGRAMS IN CANADA, 2012**  
**Proulx J**, CIHI, Ottawa, ON, Canada
- PCV103 F9 pgA147 GENERIC DRUG DISCOUNT PROGRAMS AND THEIR POTENTIAL IMPACT ON THE COMPLETENESS OF PHARMACY CLAIMS DATA**  
**Thompson JA**, Kelton CM, Heaton PC, University of Cincinnati, Cincinnati, OH, USA
- PCV104 F10 pgA147 TIMELY USE OF ACE INHIBITORS AND ARBS AFTER NEWLY DIAGNOSED DIABETES AMONG OLDER ADULTS WITH HYPERTENSION IN THE U.S**  
**Bogart M**, Fang G, Annis I, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
- PCV105 F11 pgA147 GAPS IN STATINS USE AMONG OLDER ADULTS WITH NEW ONSET DIABETES IN THE US**  
Chung TA, **Bogart M**, Annis I, Fang G, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA
- PCV106 F12 pgA147 INFLUENCE OF COST SHARING DIFFERENTIALS ON THERAPEUTIC SUBSTITUTION AND MEDICATION ADHERENCE: THE STORY OF STATINS IN 2006**  
**Li P**, Schwartz SJ, Doshi JA, University of Pennsylvania, Philadelphia, PA, USA
- PCV107 F13 pgA148 DIRECT MEDICAL COST COMPARISON BETWEEN PATIENTS RECEIVING CANGRELOR AND CLOPIDOGREL DURING PERCUTANEOUS CORONARY INTERVENTION: CHAMPION PHOENIX ECONOMIC SUB-STUDY RESULTS**  
**Nicholson G**<sup>1</sup>, Cyr P<sup>2</sup>, Fan W<sup>3</sup>, Plent S<sup>3</sup>,<sup>1</sup>ICON, plc., Los Angeles, CA, USA, <sup>2</sup>ICON Plc, Dublin, Ireland, <sup>3</sup>The Medicines Company, Parsippany, NJ, USA
- PCV108 F14 pgA148 HOSPITALIZATION COSTS FOR PATIENTS WITH HEART FAILURE USING CLAIMS DATABASE – A COMPARISON BETWEEN COMMERCIAL AND MEDICARE ADVANTAGE POPULATION**



Kielhorn A<sup>1</sup>, Maya J<sup>1</sup>, Song R<sup>2</sup>, Henk HJ<sup>2</sup>, Patel H<sup>1</sup>,<sup>1</sup>Amgen, Thousand Oaks, CA, USA, <sup>2</sup>Optum, Eden Prairie, MN, USA

**PCV109 F15** *pgA148* **CURRENT RESOURCE UTILIZATION PATTERNS IN MEDICARE BENEFICIARIES DIAGNOSED WITH HEART FAILURE**

Patel H<sup>1</sup>, Sharma P<sup>2</sup>, Maya J<sup>1</sup>, Kilgore M<sup>2</sup>, Kielhorn A<sup>1</sup>,<sup>1</sup>Amgen, Thousand Oaks, CA, USA, <sup>2</sup>Univeristy of Alabama at Birmingham, Birmingham, AL, USA

**PCV110 F16** *pgA148* **BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS ASSOCIATED WITH HEALTHCARE COSTS AMONG PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE**

Power TP<sup>1</sup>, Ke X<sup>2</sup>, Zhao Z<sup>3</sup>, Bonine N<sup>2</sup>, Cziraky MJ<sup>2</sup>, Grabner M<sup>2</sup>, Barron J<sup>4</sup>, Quimbo R<sup>2</sup>, Wertz D<sup>2</sup>, Flickinger DM<sup>3</sup>, Vangerow B<sup>3</sup>, Toth PP<sup>5</sup>,<sup>1</sup>AIM Specialty Health, Chicago, IL, USA, <sup>2</sup>HealthCore Inc., Wilmington, DE, USA, <sup>3</sup>Eli Lilly and Company, Indianapolis, IN, USA, <sup>4</sup>HealthCore, Inc, Wilmington, DE, USA, <sup>5</sup>CGH Medical Center, Sterling, IL, USA

**PCV112 G1** *pgA148* **ANNUAL HOSPITALIZATION FREQUENCY FOR PATIENTS WITH HEART FAILURE - A COMPARISON BETWEEN COMMERCIAL AND MEDICARE ADVANTAGE POPULATION**

Patel H<sup>1</sup>, Maya J<sup>1</sup>, Song R<sup>2</sup>, Henk HJ<sup>2</sup>, Kielhorn A<sup>1</sup>,<sup>1</sup>Amgen, Thousand Oaks, CA, USA, <sup>2</sup>Optum, Eden Prairie, MN, USA

**PCV113 G2** *pgA149* **ASSESSING THE HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN AMONG U.S. CARDIOVASCULAR DISEASE PATIENTS IN THE VETERANS HEALTH ADMINISTRATION POPULATION**

Mao X<sup>1</sup>, Shrestha S<sup>2</sup>, Baser O<sup>3</sup>, Wang L<sup>2</sup>,<sup>1</sup>University of Texas at Dallas and STATinMED Research, Plano, TX, USA, <sup>2</sup>STATinMED Research, Plano, TX, USA, <sup>3</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

**PCV114 G3** *pgA149* **STUDY ON THE INPATIENT HOSPITAL COSTS OF HEMORRHAGIC STROKE INPATIENTS IN CHINA**

Ma Y, Li Z, Wang L, China Health Insurance Research Association, Beijing, China

**PCV115 G4** *pgA149* **EVIDENCE REQUIREMENTS FOR FUTURE ANTIARRHYTHMIC TREATMENTS FOR ATRIAL FIBRILLATION (AF)**

Black J, Proach J, Market Access Solutions LLC, Raritan, NJ, USA

**PCV116 G5** *pgA149* **ASSESSMENT OF PAYER WILLINGNESS TO PAY FOR NOVEL HEART FAILURE THERAPIES: INCREMENTAL IMPROVEMENT IN SYMPTOM RELIEF VERSUS DISEASE MODIFYING**

Proach J, Cromer K, Black J, Market Access Solutions LLC, Raritan, NJ, USA

**PCV117 G6** *pgA149* **THE BURDEN OF UNCERTAINTY IN EMERGENCY ROOM: THE CASE OF CHEST PAIN**

Abbass IM<sup>1</sup>, Nassar A<sup>2</sup>,<sup>1</sup>The University of Texas Health Sciences Center at Houston, Houston, TX, USA, <sup>2</sup>Texas Woman's University, Houston, TX, USA

**PCV118 G7** *pgA150* **IMPACT OF MEDICAID DISCONTINUITY ON HEALTH CARE RESOURCE UTILIZATION AMONG NON-ELDERLY ADULTS WITH CARDIOVASCULAR DISEASE**

Munshi KD<sup>1</sup>, Bailey JE<sup>1</sup>, Relyea G<sup>2</sup>,<sup>1</sup>University of Tennessee Health Science Center, Memphis, TN, USA, <sup>2</sup>University of Memphis, Memphis, TN, USA

**PCV119 G8** *pgA150* **EVALUATING THE OUTCOMES OF A DIABETES TREATMENT MANAGEMENT PROGRAM TARGETING APPROPRIATE ANTI-HYPERTENSIVE TREATMENT FOR ADULTS WITH DIABETES FOR DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES**

Leung K<sup>1</sup>, Sendzik J<sup>1</sup>, Lee GC<sup>2</sup>,<sup>1</sup>Anthem, Norfolk, VA, USA, <sup>2</sup>The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA

**PCV120 G9** *pgA150* **THE IMPACT OF DIFFERENT TYPES OF HEALTH INSURANCE ON THE HOSPITALIZATION SERVICES UTILIZATION OF PATIENTS WITH HEMORRHAGIC STROKE IN CHINA**

Ma Y, Xiong X, Li J, Zhang J, China Health Insurance Research Association, Beijing, China

**PCV121 G10** *pgA150* **THE EXPANSION OF STROKE CENTERS AND THE REDUCTION OF IN-HOSPITAL MORTALITY OF ISCHEMIC STROKE PATIENTS IN ALBERTA**

Ohinmaa A<sup>1</sup>, Zheng Y<sup>1</sup>, Jeerakathil T<sup>1</sup>, Thanh NX<sup>2</sup>, Klarenbach S<sup>1</sup>, Hakkinen U<sup>3</sup>, Friesen D<sup>4</sup>, Kaul P<sup>1</sup>, Ruseski J<sup>5</sup>, Ariste R<sup>6</sup>, Jacobs P<sup>2</sup>,<sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Institute of Health Economics, Edmonton, AB, Canada, <sup>3</sup>National Institute for Health and Welfare, Helsinki, Finland, <sup>4</sup>Alberta Medical Association, Edmonton, AB, Canada, <sup>5</sup>West Virginia University, Morgantown, WV, USA, <sup>6</sup>Canadian Institute for Health Information, Ottawa, ON, Canada

**PCV122 G11** *pgA150* **THE IMPACT OF STROKE CENTERS ON THE LENGTH OF STAY AMONG ISCHEMIC STROKE PATIENTS IN ALBERTA**

Ohinmaa A<sup>1</sup>, Zheng Y<sup>1</sup>, Jeerakathil T<sup>1</sup>, Nguyen T<sup>2</sup>, Klarenbach S<sup>1</sup>, Hakkinen U<sup>3</sup>, Kaul P<sup>1</sup>, Friesen D<sup>4</sup>, Ruseski J<sup>5</sup>, Ariste R<sup>6</sup>, Jacobs P<sup>2</sup>,<sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Institute of Health Economics, Edmonton, AB, Canada, <sup>3</sup>National Institute for Health and Welfare, Helsinki, Finland, <sup>4</sup>Alberta Medical Association, Edmonton, AB, Canada, <sup>5</sup>West Virginia University, Morgantown, WV, USA, <sup>6</sup>Canadian Institute for Health Information, Ottawa, ON, Canada

**PCV123 G12** *pgA150* **PHARMACOECONOMICS RESEARCH ON DIABETES AND HYPERTENSION IN INDIA: A STUDY BASED ON PUBMED DATABASE**

Dharmagadda S<sup>1</sup>, Vooradi S<sup>2</sup>, Mateti UV<sup>1</sup>,<sup>1</sup>Dept. of Pharmacy Management, MCOPS, Manipal University,

Manipal, India, <sup>2</sup>Dept. of Pharmacy Practice, MCOPS, Manipal University, Manipal, India

**PCV124 G13 pgA151 RISK OF DIABETES WITH OR WITHOUT THE PRESENCE OF OTHER OBESITY-RELATED COMORBIDITIES (HYPERTENSION, STROKE AND CORONARY HEART DISEASE): NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY, 2007-2010**

**Leung MY**, Carlsson NP, Colditz GA, Chang S, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

**PCV125 G14 pgA151 FUNCTIONAL STATUS AND DIFFICULTY IN ACTIVITIES OF DAILY LIVING AMONG AGING POPULATION OF INDIA**

**Sakharkar P<sup>1</sup>**, Sakharkar V<sup>2</sup>, <sup>1</sup>Roosevelt University College of Pharmacy, Schaumburg, IL, USA, <sup>2</sup>UWI-School of Clinical Medicine and Research, Nassau, Bahamas

**PCV126 G15 pgA151 PREVALENCE AND OUTCOMES OF GLOBAL VASCULAR HOSPITAL ADMISSIONS IN ARGENTINA**

**Insua J**, Hospital Universitario Austral, Pacheco, Argentina

**PCV127 G16 pgA151 DEPRESSION TREATMENT AMONG WOMEN WITH CARDIO-METABOLIC CONDITIONS: FINDINGS FROM MEDICAL EXPENDITURE PANEL SURVEY 2012**

**Raval A**, Sambamoorthi U, West Virginia University, Morgantown, WV, USA

**PCV128 G17 pgA151 PATTERNS OF TREATMENT MODIFICATIONS IN NEWLY TREATED HYPERTENSIVE PATIENTS: DOES CHOICE OF MODIFICATION STRATEGY AFFECT LIKELIHOOD OF TREATMENT DISCONTINUATION?**

**Sonawane KB<sup>1</sup>**, Qian J<sup>1</sup>, Garza KB<sup>1</sup>, Wright BM<sup>1</sup>, Zeng P<sup>1</sup>, Ganduglia Cazaban CM<sup>2</sup>, Hansen RA<sup>1</sup>, <sup>1</sup>Auburn University, Auburn, AL, USA, <sup>2</sup>University of Texas School of Public Health, Houston, TX, USA

**PCV129 G18 pgA152 REAL-WORLD STATIN UTILIZATION AMONG PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS: US ANALYSES**

**Lin J<sup>1</sup>**, Sung JC<sup>2</sup>, Sanchez R<sup>3</sup>, Mallya UG<sup>2</sup>, Friedman M<sup>1</sup>, Panaccio M<sup>2</sup>, Koren A<sup>2</sup>, Neumann PJ<sup>4</sup>, Menzin J<sup>1</sup>, Boston Health Economics, Inc., Waltham, MA, USA, <sup>2</sup>Sanofi US, Inc., Bridgewater, NJ, USA, <sup>3</sup>Regeneron Pharmaceuticals, Tarrytown, NY, USA, <sup>4</sup>Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

**PCV130 G19 pgA152 TREATMENT PATTERN AND OUTCOMES OF INTRAVENOUS ANTIHYPERTENSIVE AGENTS IN US HOSPITAL ICH PATIENTS**

**Wang Y**, Plent S, Crothers TA, The Medicines Company, Parsippany, NJ, USA

**PCV131 G20 pgA152 VENOUS THROMBOEMBOLISM TREATMENT PATTERNS IN THE EUROPEAN UNION (EU) REGION: 2013 RETROSPECTIVE CHART EXTRACTION**

**Gupta S<sup>1</sup>**, Goren A<sup>2</sup>, Yaniv R<sup>3</sup>, Unniachan S<sup>4</sup>, Phatak H<sup>5</sup>, Masseria C<sup>6</sup>, Hamilton M<sup>7</sup>, Liu X<sup>3</sup>, <sup>1</sup>Kantar Health, Princeton, NJ, USA, <sup>2</sup>Kantar Health, New York, NY, USA, <sup>3</sup>Pfizer Inc, New York, NY, USA, <sup>4</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>5</sup>Bristol-Myers Squibb Company, Princeton, NJ, USA, <sup>6</sup>Pfizer Inc., New York, NY, USA, <sup>7</sup>BMS, Princeton, NJ, USA

---

## MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies

**PMS1 G21 pgA152 TREATMENT WITH SOME BISPHOSPHONATES IS ASSOCIATED WITH AORTIC AND MITRAL VALVE CALCIFICATION**

**Ali AK**, Eli Lilly and Company, Indianapolis, IN, USA

**PMS2 H1 pgA152 SAFETY OF TOFACITINIB COMPARED TO BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE: OVERVIEW OF SYSTEMATIC REVIEWS**

**Reyes JM<sup>1</sup>**, Rodriguez A<sup>2</sup>, <sup>1</sup>Pfizer SAS, Bogota, Colombia, <sup>2</sup>Universidad Nacional de Colombia, Bogota, Colombia

**PMS3 H2 pgA153 FACTORS AND REASONS ASSOCIATED WITH SWITCHING IN RHEUMATOID ARTHRITIS PATIENTS EXPERIENCED ON BIOLOGIC DMARDS AND IMPACT ON HEALTH CARE RESOURCE UTILIZATION IN AN INTEGRATED HEALTHCARE SYSTEM**

**Rashid N<sup>1</sup>**, Patel C<sup>2</sup>, Li Z<sup>1</sup>, Guerrero V<sup>1</sup>, Nadkarni A<sup>2</sup>, Aranda G<sup>2</sup>, <sup>1</sup>Kaiser Permanente, SCAL Region, Downey, CA, USA, <sup>2</sup>BMS, Plainsboro, NJ, USA

**PMS4 H3 pgA153 FACTORS AND REASONS ASSOCIATED WITH SWITCHING IN RHEUMATOID ARTHRITIS PATIENTS NEWLY INITIATED ON BIOLOGIC DMARDS AND IMPACT ON HEALTH CARE RESOURCE UTILIZATION IN A MANAGED CARE ORGANIZATION**

**Rashid N<sup>1</sup>**, Aranda G<sup>2</sup>, Li Z<sup>1</sup>, Guerrero V<sup>1</sup>, Nadkarni A<sup>2</sup>, Patel C<sup>2</sup>, <sup>1</sup>Kaiser Permanente, SCAL Region, Downey, CA, USA, <sup>2</sup>BMS, Plainsboro, NJ, USA

**PMS5 H4 pgA153 META-ANALYSIS OF EFFICACY AND SAFETY OF DENOSUMAB IN POSTMENOPAUSAL OSTEOPOROSIS**

**Xuan S<sup>1</sup>**, Ma J<sup>2</sup>, Liu GG<sup>3</sup>, <sup>1</sup>Yale University, New Haven, CT, USA, <sup>2</sup>University of Utah, Salt Lake City, UT, USA, <sup>3</sup>Peking University, Beijing, China

**PMS6 H5 pgA153 ADVERSE DRUG REACTIONS ASSOCIATED WITH THE USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS**

**Machado J<sup>1</sup>**, Ruiz A<sup>2</sup>, Machado-Duque M<sup>1</sup>, <sup>1</sup>Universidad Tecnológica de Pereira, Pereira, Colombia, <sup>2</sup>Glaxo, Bogota, Colombia

**PMS7 H6 pgA153 INCIDENCE AND PROGNOSTIC FACTORS FOR CONTRALATERAL HIP FRACTURE AMONG HUNGARIAN MEN OVER 60 YEARS**

- Juhász K<sup>1</sup>, Gajdácsi J<sup>2</sup>, **Boncz I**<sup>3</sup>, Molics B<sup>3</sup>, Sebestyén A<sup>3</sup>,<sup>1</sup>National Health Insurance Fund Administration, Pécs, Hungary, <sup>2</sup>National Health Insurance Fund Administration, Budapest, Hungary, <sup>3</sup>University of Pécs, Pécs, Hungary
- PMS8 H7** *pgA154* **HOSPITAL-REPORTED FREQUENCY & EXCESS COST OF FOREIGN OBJECTS LEFT IN THE BODY DURING TOTAL JOINT ARTHROPLASTY**  
**Van Doren BA**<sup>1</sup>, Odum SM<sup>1</sup>, Curtin B<sup>2</sup>,<sup>1</sup>OrthoCarolina Research Institute, Inc., Charlotte, NC, USA, <sup>2</sup>OrthoCarolina Hip & Knee Center, Charlotte, NC, USA
- PMS9 H8** *pgA154* **ASSOCIATION BETWEEN SEDATIVE-HYPNOTICS USE AND FALLS IN COMMUNITY-DWELLING OLDER ADULTS**  
**Park Y**<sup>1</sup>, Tom S<sup>2</sup>, Stuart B<sup>2</sup>,<sup>1</sup>University of Maryland College of Pharmacy, Baltimore, MD, USA, <sup>2</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA
- PMS10 H9** *pgA154* **RELATIONSHIP OF SERUM URIC ACID LEVELS WITH HYPERTENSION AND HYPERLIPIDEMIA IN PATIENTS WITH GOUT**  
**Essex MN**<sup>1</sup>, Hopps M<sup>1</sup>, Udall M<sup>1</sup>, Fu C<sup>2</sup>, Mardekian J<sup>3</sup>, Bienen EJ<sup>4</sup>, Makinson G<sup>1</sup>,<sup>1</sup>Pfizer Inc., New York, NY, USA, <sup>2</sup>Inventiv Health, Chesterbrook, PA, USA, <sup>3</sup>Pfizer, New York, NY, USA, <sup>4</sup>Outcomes Consultant, New York, NY, USA
- PMS11 H10** *pgA154* **LITERATURE REVIEW - DOES THE CHARACTERIZATION OF AXIAL SPA DIFFER FOR BURDEN OF ILLNESS BETWEEN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ANKYLOSING SPONDYLITIS**  
Sanders KN<sup>1</sup>, **Adesanoye D**<sup>2</sup>,<sup>1</sup>Pfizer, Inc., New York, NY, USA, <sup>2</sup>University of Rhode Island College of Pharmacy, Kingston, RI, USA
- PMS12 H11** *pgA154* **BISPHOSPHONATES FOR FRACTURE PREVENTION IN MALES – A SYSTEMATIC REVIEW AND META-ANALYSIS**  
**Cheng Y**<sup>1</sup>, Jiao T<sup>1</sup>, Willson T<sup>2</sup>, Reese T<sup>1</sup>, Stoddard GJ<sup>1</sup>, LaFleur J<sup>1</sup>,<sup>1</sup>University of Utah, Salt Lake City, UT, USA, <sup>2</sup>Truven Health Analytics, Salt Lake City, UT, USA
- PMS13 H12** *pgA154* **COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)**  
**Narayanan S**<sup>1</sup>, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baynton E<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS14 H13** *pgA155* **EFFICACY OF TOFACITINIB IN COMBINATION WITH METHOTREXATE COMPARED TO BIOLOGICAL DMARDS IN COMBINATION WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE: OVERVIEW OF SYSTEMATIC REVIEW**  
**Reyes JM**<sup>1</sup>, Rodriguez A<sup>2</sup>,<sup>1</sup>Pfizer SAS, Bogota, Colombia, <sup>2</sup>Universidad Nacional, Bogota, Colombia
- PMS15 H14** *pgA155* **COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH PSORIATIC ARTHRITIS (PSA) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)**  
**Narayanan S**<sup>1</sup>, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baynton E<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS16 H15** *pgA155* **ASSESSMENT OF THE QUALITY OF LIFE IN CHINESE MYASTHENIA GRAVIS PATIENTS**  
**Zhang HY**, Xie WF, Zhang JS, Yang GL,<sup>1</sup>Liaoning University of Traditional Chinese Medicine, Shenyang, China
- PMS17 H16** *pgA155* **LONG-TERM DECREASE IN GOUT FLARE RATES ASSOCIATED WITH EFFECTIVE URATE LOWERING THERAPY**  
**Kelton K**,<sup>1</sup>Medical Decision Modeling, Indianapolis, IN, USA
- PMS18 H17** *pgA155* **USE OF ANTI-OSTEOPOROSIS MEDICATIONS AND FRACTURE RISK AMONG ELDERLY PATIENTS WITH END-STAGE RENAL DISEASE: A RETROSPECTIVE COHORT STUDY**  
**Lo P**<sup>1</sup>, Tsai H<sup>2</sup>, Chao C<sup>2</sup>, Peng L<sup>3</sup>, Tsai Y<sup>1</sup>, Chen L<sup>3</sup>,<sup>1</sup>National Yang Ming University, Taipei, Taiwan, <sup>2</sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>3</sup>Taipei Veterans General Hospital, Taipei, Taiwan
- PMS19 H18** *pgA156* **TREATMENT MODIFICATIONS AND COSTS OF BIOLOGIC THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS**  
**Palmer JB**<sup>1</sup>, Li Y<sup>1</sup>, Herrera V<sup>1</sup>, Tsang Y<sup>1</sup>, Liao M<sup>2</sup>, Ozturk Z<sup>1</sup>,<sup>1</sup>Novartis Pharmaceuticals, East Hanover, NJ, USA, <sup>2</sup>KMK Consulting Inc., Florham Park, NJ, USA
- PMS20 H19** *pgA156* **LONG-TERM FAILURE RATES ASSOCIATED WITH KNEE MICROFRACTURE SURGERY**  
**Layton A**<sup>1</sup>, Arnold RJ<sup>1</sup>, Graham J<sup>1</sup>, Frasco MA<sup>1</sup>, Cote E<sup>2</sup>, Lynch NM<sup>2</sup>,<sup>1</sup>Quorum Consulting, San Francisco, CA, USA, <sup>2</sup>Histogenics Corporation, Waltham, MA, USA
- PMS21 H20** *pgA156* **EVALUATION OF PROGNOSTIC FACTORS FOR CONTRALATERAL HIP FRACTURE AMONG ELDERLY WOMEN IN HUNGARY: A 8-YEAR NATIONWIDE STUDY**  
Juhász K<sup>1</sup>, Gajdácsi J<sup>2</sup>, **Boncz I**<sup>3</sup>, Molics B<sup>3</sup>, Sebestyén A<sup>3</sup>,<sup>1</sup>National Health Insurance Fund Administration, Pécs, Hungary, <sup>2</sup>National Health Insurance Fund Administration, Budapest, Hungary, <sup>3</sup>University of Pécs, Pécs, Hungary
- PMS22 H21** *pgA156* **INCREASED RISK OF OSTEOPENIA AMONG HIV-POSITIVE ADULTS AGES18-49**  
**Cheng Y**<sup>1</sup>, Pan Q<sup>2</sup>, Alder RA<sup>3</sup>, LaFleur J<sup>1</sup>,<sup>1</sup>University of Utah, Salt Lake City, UT, USA, <sup>2</sup>Zhejiang Pharmaceutical College, Ningbo, Zhejiang Province, China, <sup>3</sup>Virginia Commonwealth University, Richmond, VA, USA
- PMS23 I1** *pgA156* **MULTINOMINAL LOGISTIC REGRESSION ANALYSIS OF RISK FACTORS INFLUENCING THE TIME UNTIL SECONDARY HIP FRACTURES**

- Juhász K<sup>1</sup>, Gajdácsi J<sup>2</sup>, **Boncz I**<sup>3</sup>, Molics B<sup>3</sup>, Sebestyén A<sup>3</sup>,<sup>1</sup>National Health Insurance Fund Administration, Pécs, Hungary, <sup>2</sup>National Health Insurance Fund Administration, Budapest, Hungary, <sup>3</sup>University of Pécs, Pécs, Hungary
- PMS24 I2** *pgA156* **RELATIONSHIP OF SEDENTARY BEHAVIOR WITH QALYS IN COMMUNITY DWELLING ADULTS WITH OR AT RISK FOR KNEE OSTEOARTHRITIS**  
**Pinto D**<sup>1</sup>, Song J<sup>1</sup>, Chang RW<sup>1</sup>, Semanik PA<sup>2</sup>, Ehrlich-Jones L<sup>3</sup>, Pellegrini CA<sup>1</sup>, Dunlop DD<sup>1</sup>,<sup>1</sup>Northwestern University, Chicago, IL, USA, <sup>2</sup>Rush University, Chicago, IL, USA, <sup>3</sup>Rehabilitation Institute of Chicago, Chicago, IL, USA

---

#### MUSCULAR-SKELETAL DISORDERS - Cost Studies

- PMS25 I3** *pgA157* **VALIDATION OF A BUDGET IMPACT MODEL FOR USE OF DENOSUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS**  
**Mehta D**<sup>1</sup>, Stolshek B<sup>2</sup>, Agodoa I<sup>2</sup>,<sup>1</sup>Clinical Pharmacy and Pharmaceutical Economics & Policy, Leonard D. Schaeffer Center for Health Policy and Economics, School of Pharmacy, University of Southern California, USA, Los Angeles, CA, USA, <sup>2</sup>Amgen Inc., Thousand Oaks, CA, USA
- PMS26 I4** *pgA157* **BUDGET IMPACT ANALYSIS OF BOTULINUM TOXIN A THERAPY FOR UPPER LIMB SPASTICITY IN HONG KONG**  
**Dinet J**<sup>1</sup>, Nai Mo LAM E<sup>2</sup>, Gabriel S<sup>3</sup>,<sup>1</sup>Ipsen Pharma, Boulogne-Billancourt, France, <sup>2</sup>Beaufour Ipsen Tianjin Pharmaceutical Co, TIANJIN, China, <sup>3</sup>IPSEN Pharma, Boulogne Billancourt, France
- PMS27 I5** *pgA157* **BUDGET IMPACT ANALYSIS OF THE INCLUSION OF TOFACITINIB IN THE PUBLIC LIST OF REIMBURSEMENT IN THE TREATMENT OF RHEUMATOID ARTHRITIS AFTER INADEQUATE RESPONSE TO METHOTREXATE IN COLOMBIA**  
Vargas-Valencia J<sup>1</sup>, **Prieto VA**<sup>2</sup>, Jáuregui E<sup>3</sup>, Fernandez-Avila D<sup>4</sup>, Chalem-Choueka MR<sup>5</sup>, Vasquez G<sup>6</sup>,<sup>1</sup>Econopharma Consulting, Mexico, Mexico, <sup>2</sup>Pfizer SAS, Bogota, Colombia, <sup>3</sup>Riesgo de Fractura, Bogota, Colombia, <sup>4</sup>Hospital Universitario San Ignacio, Bogota, Colombia, <sup>5</sup>Universidad del Bosque, Bogota, Colombia, <sup>6</sup>Universidad de Antioquia, Medellin, Colombia
- PMS28 I6** *pgA157* **BUDGET IMPACT ANALYSIS OF BOTULINIUM TOXIN TYPE A IN TREATMENT OF POST-STROKE SPASTICITY IN THE RUSSIAN FEDERATION**  
**Yagudina R**, Kulikov A, Ugrekhelidze D.I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- PMS29 I7** *pgA157* **RECENT COST TRENDS AMONG PATIENTS USING BIOLOGIC AGENTS FOR THE TREATMENT OF PSORIATIC ARTHRITIS**  
**Kuznik A**<sup>1</sup>, Eslava S<sup>2</sup>, Cai J<sup>3</sup>,<sup>1</sup>Celgene Corporation, Warren, NJ, USA, <sup>2</sup>Celgene Corporation, Berkeley Heights, NJ, USA, <sup>3</sup>Celgene Corporation, Summit, NJ, USA
- PMS30 I8** *pgA157* **MODELING OF SOCIETAL COSTS UNDER DIFFERENT TREATMENT SCHEMES OF POST-STROKE SPASTICITY IN THE RUSSIAN FEDERATION**  
**Yagudina R**, Kulikov A, Ugrekhelidze D.I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- PMS31 I9** *pgA158* **GENERIC SWITCH EVALUATION OF CELEBREX® IN PATIENTS WITH OSTEOARTHRITIS (OA) USING A RETROSPECTIVE CLAIMS DATABASE**  
**Ji X**<sup>1</sup>, Liu S<sup>1</sup>, Solem CT<sup>1</sup>, Shelbaya A<sup>2</sup>, Walker C<sup>3</sup>, Cappelleri JC<sup>4</sup>, Gao X<sup>1</sup>, Stephens JM<sup>1</sup>,<sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Pfizer, Inc, New York, NY, USA, <sup>3</sup>Pfizer, Inc, Tadworth, Surrey, UK, <sup>4</sup>Pfizer Inc, Groton, CT, USA
- PMS32 I10** *pgA158* **THE COST-EFFECTIVENESS OF MENISCAL REPAIR VERSUS PARTIAL MENISCECTOMY: A MODEL-BASED PROJECTION OF CLINICAL OUTCOMES AND COSTS IN THE UNITED STATES HEALTHCARE SYSTEM**  
Feeley B<sup>1</sup>, Liu S<sup>2</sup>, Garner AM<sup>3</sup>, Zhang A<sup>1</sup>, **Pietzsch JB**<sup>3</sup>,<sup>1</sup>University of California San Francisco, San Francisco, CA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA, <sup>3</sup>Wing Tech Inc., Menlo Park, CA, USA
- PMS33 I11** *pgA158* **COMPARING BURDEN OF ILLNESS OF TOPHACEOUS WITH NON-TOPHACEOUS GOUT PATIENTS USING A LARGE US ELECTRONIC HEALTH RECORDS DATABASE**  
**Rudell K**<sup>1</sup>, Bobula J<sup>2</sup>, Fu C<sup>3</sup>, Mardekian J<sup>4</sup>, Sadosky A<sup>5</sup>, Essex M<sup>5</sup>, Taylor W<sup>6</sup>,<sup>1</sup>Pfizer Ltd, Tadworth, UK, <sup>2</sup>Pfizer Inc, Collegeville, PA, USA, <sup>3</sup>Inventiv Health, Chesterbrook, PA, USA, <sup>4</sup>Pfizer, Inc., New York, NY, USA, <sup>5</sup>Pfizer Inc, New York, NY, USA, <sup>6</sup>University of Otago, Wellington, Wellington, New Zealand
- PMS34 I12** *pgA158* **DISEASE BURDEN OF PSORIATIC ARTHRITIS IN TAIWAN: A POPULATION-BASED ANALYSIS**  
Wang BC<sup>1</sup>, Tang C<sup>2</sup>, Furnback W<sup>1</sup>, Ney JP<sup>3</sup>, **Yang Y**<sup>4</sup>, Fang C<sup>4</sup>, Huang Y<sup>5</sup>,<sup>1</sup>Alliance Life Sciences, Somerset, NJ, USA, <sup>2</sup>Taipei Medical University, Taipei, Taiwan, <sup>3</sup>University of Washington, Seattle, WA, USA, <sup>4</sup>Pfizer Limited, New Taipei City, Taiwan, <sup>5</sup>Chang Gung Memorial Hospital, Taipei, Taiwan
- PMS35 I13** *pgA158* **COSTS DESCRIPTION OF RHEUMATOID ARTHRITIS TREATMENT IN CHILE FOR PATIENTS WHO HAVE FAILED TO CONVENTIONAL SYNTHETIC DMARDS**  
De la Puente A C<sup>1</sup>, Zaror S C<sup>1</sup>, Velasquez Z M<sup>1</sup>, Bustos Medina L<sup>1</sup>, **Gutierrez-Ardila MV**<sup>2</sup>,<sup>1</sup>Universidad de La Frontera, Temuco, Chile, <sup>2</sup>Pfizer Chile S.A., Santiago, Chile
- PMS36 I14** *pgA159* **COMORBIDITY BURDEN AND INCREMENTAL COST OF FRACTURES IN MEDICARE MEN WITH NON-METASTATIC PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY**  
**Yong C**<sup>1</sup>, Onukwugha E<sup>1</sup>, Mullins CD<sup>1</sup>, Zuckerman IH<sup>2</sup>, Hussain A<sup>3</sup>, Naslund M<sup>3</sup>,<sup>1</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA, <sup>2</sup>IMPAQ International, LLC, Columbia, MD, USA, <sup>3</sup>University of Maryland School of Medicine, Baltimore, MD, USA



- PMS37 J1** *pgA159* **HEALTH CARE COST BURDEN AND DEMOGRAPHIC DISTRIBUTION OF PATIENTS DIAGNOSED WITH PSORIATIC ARTHRITIS IN THE U.S. MEDICARE POPULATION**  
Li L<sup>1</sup>, Mao X<sup>2</sup>, Shrestha S<sup>1</sup>, Baser O<sup>3</sup>, Yuce H<sup>4</sup>, Wang L<sup>1</sup>,<sup>1</sup>STATinMED Research, Plano, TX, USA, <sup>2</sup>University of Texas at Dallas and STATinMED Research, Plano, TX, USA, <sup>3</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, <sup>4</sup>City University of New York & STATinMED Research, New York, NY, USA
- PMS38 J2** *pgA159* **DEMOGRAPHIC DISTRIBUTION AND ECONOMIC BURDEN OF PATIENTS DIAGNOSED WITH RHEUMATOID ARTHRITIS IN THE U.S. MEDICARE POPULATION**  
Li L<sup>1</sup>, Mao X<sup>2</sup>, Shrestha S<sup>1</sup>, Baser O<sup>3</sup>, Yuce H<sup>4</sup>, Wang L<sup>1</sup>,<sup>1</sup>STATinMED Research, Plano, TX, USA, <sup>2</sup>University of Texas at Dallas and STATinMED Research, Plano, TX, USA, <sup>3</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, <sup>4</sup>City University of New York & STATinMED Research, New York, NY, USA
- PMS39 J3** *pgA159* **COMPARATIVE RISK OF TRANSFUSION AND INCREMENTAL TOTAL HOSPITALIZATION COST OF PRIMARY UNILATERAL, BILATERAL, AND REVISION TOTAL KNEE ARTHROPLASTY PROCEDURES**  
Nichols CI, Vose JG, Medtronic Advanced Energy, Portsmouth, NH, USA
- PMS40 J4** *pgA159* **PATIENT COMORBIDITY STATUS AND INCREMENTAL TOTAL HOSPITALIZATION COSTS IN ELECTIVE ORTHOPEDIC PROCEDURES**  
Nichols CI, Vose JG, Medtronic Advanced Energy, Portsmouth, NH, USA
- PMS41 J5** *pgA160* **ONE-YEAR COST OUTCOMES OF EARLY PHYSICAL THERAPY (PT) COMPARED WITH A USUAL CARE APPROACH FOR PATIENTS WITH ACUTE LOW BACK PAIN (LBP) CONSULTING PRIMARY CARE**  
Fritz J<sup>1</sup>, Kim M<sup>2</sup>, Magel J<sup>1</sup>, Asche CV<sup>2</sup>,<sup>1</sup>University of Utah, Salt Lake City, UT, USA, <sup>2</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA
- PMS42 J6** *pgA160* **BLOOD LOSS AND ECONOMIC BURDEN COMPONENTS OF SPINAL FUSION SURGERY IN ADOLESCENT SCOLIOSIS AND ADULT DEFORMITY**  
Hsiao C<sup>1</sup>, Tao C<sup>2</sup>, Chawla AS<sup>3</sup>, Faulkner EC<sup>4</sup>, Cheng H<sup>1</sup>,<sup>1</sup>Ethicon Inc., Cincinnati, OH, USA, <sup>2</sup>Quintiles Consulting, Cambridge, MA, USA, <sup>3</sup>Quintiles Consulting, Durham, NC, USA, <sup>4</sup>Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
- PMS43 J7** *pgA160* **EVALUATING CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH LIPOSOMAL BUPIVACAINE (LB) FOR POSTSURGICAL PAIN FOLLOWING TOTAL KNEE ARTHROPLASTY (TKA)**  
Asche CV<sup>1</sup>, Kirkness CS<sup>1</sup>, Ren J<sup>1</sup>, Kim M<sup>1</sup>, Rainville E<sup>2</sup>,<sup>1</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>2</sup>OSF Saint Francis Medical Center, Peoria, IL, USA
- PMS44 J8** *pgA160* **A SYSTEMATIC LITERATURE REVIEW OF THE COST-EFFECTIVENESS OF ERYTHROPOIETIN IN ORTHOPEDIC SURGERY: THERE IS A NEED FOR DIFFERENTIATION BETWEEN TOTAL HIP AND KNEE ARTHROPLASTY**  
Degener F, Postma MJ, University of Groningen, Groningen, The Netherlands
- PMS45 J9** *pgA160* **RESULTS OF THE INCLUSION OF NEW MEDICATIONS IN THE OBLIGATORY HEALTH SYSTEM PLAN IN COLOMBIA, 2012-2013**  
Machado J<sup>1</sup>, Arias A<sup>2</sup>, Torres D<sup>1</sup>, Portilla A<sup>1</sup>,<sup>1</sup>Universidad Tecnológica de Pereira, Pereira, Colombia, <sup>2</sup>Glaxo, Bogota, Colombia
- PMS46 J10** *pgA160* **THE ECONOMIC VALUE OF TOFACITINIB 5 MG BID IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS: A CANADIAN ANALYSIS**  
Woolcott JC<sup>1</sup>, Blackhouse G<sup>2</sup>, Claxton L<sup>3</sup>, Wallenstein G<sup>4</sup>, Tran T<sup>1</sup>, Goeree R<sup>5</sup>, Taylor M<sup>3</sup>, Moynagh D<sup>6</sup>, Singh A<sup>6</sup>,<sup>1</sup>Pfizer Canada Inc, Kirkland, QC, Canada, <sup>2</sup>PATH Research Institute, St. Joseph's Health Care Hamilton/McMaster University, Hamilton, ON, Canada, <sup>3</sup>York Health Economics Consortium, University of York, York, UK, <sup>4</sup>Pfizer Inc, Groton, CT, USA, <sup>5</sup>McMaster University, Hamilton, ON, Canada, <sup>6</sup>Pfizer Inc, Collegeville, PA, USA
- PMS47 J11** *pgA161* **MODELLING THE COSTS AND OUTCOMES ASSOCIATED WITH SEQUENCE OF TREATMENT WITH AND WITHOUT TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE US**  
Claxton L<sup>1</sup>, Taylor M<sup>1</sup>, Moynagh D<sup>2</sup>, Gruben D<sup>3</sup>, Wallenstein G<sup>3</sup>, Singh A<sup>2</sup>,<sup>1</sup>York Health Economics Consortium, University of York, York, UK, <sup>2</sup>Pfizer Inc, Collegeville, PA, USA, <sup>3</sup>Pfizer Inc, Groton, CT, USA
- PMS48 J12** *pgA161* **COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF INADEQUATELY RESPONDING RHEUMATOID ARTHRITIS PATIENTS**  
Hansen RN<sup>1</sup>, Best JH<sup>2</sup>, Sullivan SD<sup>3</sup>, Carlson JJ<sup>3</sup>,<sup>1</sup>School of Pharmacy, University of Washington, Seattle, WA, USA, <sup>2</sup>Genentech, Inc, South San Francisco, CA, USA, <sup>3</sup>University of Washington, Seattle, WA, USA
- PMS49 J13** *pgA161* **COST-EFFECTIVENESS ANALYSIS OF CONDOLIASE IN PATIENTS WITH LUMBAR DISC HERNIATION IN JAPAN**  
Ikeda S<sup>1</sup>, Inoue S<sup>2</sup>, Kobayashi M<sup>2</sup>,<sup>1</sup>International University of Health and Welfare, Otawara City, Tochigi, Japan, <sup>2</sup>CRECON Medical Assessment Inc., Tokyo, Japan
- PMS50 J14** *pgA161* **ECONOMIC EVALUATION OF TOFACITINIB AS INITIAL MEDICATION IN ADULTS WITH RHEUMATOID ARTHRITIS AFTER FAILURE TO METHOTREXATE IN CHILE**  
Velasquez Z M<sup>1</sup>, Bustos Medina L<sup>1</sup>, De la Puente A C<sup>1</sup>, Zaror S C<sup>1</sup>, Gutierrez-Ardila MV<sup>2</sup>,<sup>1</sup>Universidad de La Frontera, Temuco, Chile, <sup>2</sup>Pfizer Chile S.A., Santiago, Chile

- PMS51 K1** *pgA161* **WHAT IS THE COST-EFFECTIVE BEARING SURFACE CHOICE IN PRIMARY TOTAL HIP ARTHROPLASTY**  
**Carnes KJ**<sup>1</sup>, Odum SM<sup>2</sup>, Troyer JL<sup>1</sup>, Fehring TK<sup>3</sup>,<sup>1</sup>University of North Carolina at Charlotte, Charlotte, NC, USA, <sup>2</sup>OrthoCarolina Research Institute, Inc., Charlotte, NC, USA, <sup>3</sup>OrthoCarolina Hip and Knee Center, Charlotte, NC, USA
- PMS52 K2** *pgA162* **COST-EFFECTIVENESS ANALYSIS OF CERTOLIZUMAB, ETANERCEPT, GOLIMUMAB AND TOFACITINIB FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS**  
**Han X**, Hay JW, University of Southern California, Los Angeles, CA, USA
- PMS53 K3** *pgA162* **ECONOMIC EVALUATION OF TREATMENT SEQUENCES FOR THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN THE ECUATORIAN PUBLIC HEALTHCARE SECTOR**  
Rosado-Buzzo A<sup>1</sup>, **Luna-Casas G**<sup>2</sup>, Garcia-Molliendo L<sup>2</sup>, Albuja M<sup>3</sup>,<sup>1</sup>Linkd and Links, Mexico City, Mexico, <sup>2</sup>Links and Links, Mexico City, Mexico, <sup>3</sup>Pfizer Ecuador, Quito, Mexico
- PMS54 K4** *pgA162* **COST EFFECTIVENESS OF TOFACITINIB AS SECOND LINE TREATMENT VS USING BIOLOGICAL THERAPIES IN THE TREATMENT OF MODERATE RHEUMATOID ARTHRITIS AFTER FAILURE OF DMARDS IN PANAMA IN 2014**  
**Garita-Aguilar M**<sup>1</sup>, Peralta-Acon M<sup>1</sup>, Gorriiz-Añorbes L<sup>2</sup>,<sup>1</sup>Pfizer Central America and Caribbean, San José, Costa Rica, <sup>2</sup>Ministerio de Salud de Panamá, Ciudad de Panamá, Panama
- PMS55 K5** *pgA162* **ECONOMIC EVALUATION OF TIMELY VERSUS DELAYED USE OF ANTI-TUMOR NECROSIS FACTOR (TNF) BIOLOGICS IN THE TREATMENT OF PSORIATIC ARTHRITIS (PSA) IN THE US**  
Zhou Z<sup>1</sup>, Signorovitch JE<sup>2</sup>, **Griffith JM**<sup>3</sup>, Zhong Y<sup>1</sup>, Ganguli A<sup>3</sup>,<sup>1</sup>Analysis Group Inc., Boston, MA, USA, <sup>2</sup>Analysis Group, Inc., Boston, MA, USA, <sup>3</sup>Abbvie Inc., North Chicago, IL, USA
- PMS56 K6** *pgA162* **ECONOMIC ANALYSIS OF BIOLOGIC ALTERNATIVES IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS, PSORIASIS AND ANKYLOSING SPONDYLITIS FROM PUBLIC AND PRIVATE PERSPECTIVES IN BRAZIL**  
**Ferreira CN**<sup>1</sup>, Rufino CS<sup>1</sup>, Amaral LM<sup>2</sup>, Fernandes RA<sup>2</sup>,<sup>1</sup>Pfizer Brasil, São Paulo, Brazil, <sup>2</sup>MedInsight, Rio de Janeiro, Brazil
- PMS57 K7** *pgA162* **COST-EFFECTIVENESS ANALYSIS OF BISPHOSPHONATES FOR SECONDARY PREVENTION OF HIP FRACTURE IN TAIWAN**  
**Lo P**<sup>1</sup>, Wen Y<sup>2</sup>, Tsai Y<sup>1</sup>,<sup>1</sup>National Yang Ming University, Taipei, Taiwan, <sup>2</sup>Chang Gung University, Taoyuan, Taiwan
- PMS58 K8** *pgA163* **COST EFFECTIVENESS OF TOFACITINIB AS SECOND LINE TREATMENT VS USING BIOLOGICAL THERAPIES IN THE TREATMENT OF MODERATE RHEUMATOID ARTHRITIS AFTER FAILURE OF DMARDS IN GUATEMALA IN 2014**  
**Garita-Aguilar M**<sup>1</sup>, Peralta-Acon M<sup>1</sup>, Chavez-Perez N<sup>2</sup>,<sup>1</sup>Pfizer Central America and Caribbean, San José, Costa Rica, <sup>2</sup>Instituto Guatemalteco del Seguro Social, Ciudad de Guatemala, Guatemala
- PMS59 K9** *pgA163* **ASSOCIATION BETWEEN OSTEOARTHRITIS AND WORKPLACE ABSENTEEISM**  
**Menon J**, Thomas III J, Purdue University, West Lafayette, IN, USA

---

#### MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PMS60 K10** *pgA163* **BIOLOGIC DISCONTINUATION IN RHEUMATOID ARTHRITIS: EXPERIENCE FROM CANADIAN CLINICS**  
Choquette D<sup>1</sup>, Coupal L<sup>1</sup>, **Laliberté M**<sup>2</sup>, Desjardins O<sup>2</sup>,<sup>1</sup>Institut de Rhumatologie de Montréal, Montreal, QC, Canada, <sup>2</sup>AbbVie, Saint-Laurent, QC, Canada
- PMS61 K11** *pgA163* **PATIENT- AND PHYSICIAN-REPORTED MOTIVATIONS FOR MEDICATION NON-ADHERENCE OR SWITCHING IN RHEUMATOID ARTHRITIS**  
**Smalarz A**<sup>1</sup>, Prado M<sup>2</sup>,<sup>1</sup>Strategic Market Insight, Acton, MA, USA, <sup>2</sup>Real Health Data, Santa Cruz, CA, USA
- PMS62 K12** *pgA163* **IMPACT OF RHEUMATOID ARTHRITIS ON SELF-REPORTED WORK PRODUCTIVITY, DISEASE SEVERITY AND ADHERENCE IN AN EMPLOYED POPULATION**  
**Kamal KM**<sup>1</sup>, Ghosh S<sup>1</sup>, Koerner P<sup>1</sup>, Miller R<sup>2</sup>, Parekh MH<sup>1</sup>, Khairnar R<sup>1</sup>,<sup>1</sup>Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA, <sup>2</sup>Walgreens Specialty Pharmacy, Carnegie, PA, USA
- PMS63 K13** *pgA164* **RELATIONSHIP BETWEEN MEDICATION ADHERENCE, DISEASE SEVERITY AND EMPLOYMENT STATUS IN RHEUMATOID ARTHRITIS**  
**Ghosh S**<sup>1</sup>, Kamal KM<sup>1</sup>, Koerner P<sup>1</sup>, Miller R<sup>2</sup>, Parekh MH<sup>1</sup>, Khairnar R<sup>1</sup>,<sup>1</sup>Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA, <sup>2</sup>Walgreens Specialty Pharmacy, Carnegie, PA, USA
- PMS64 K14** *pgA164* **EVALUATION OF DISEASE ACTIVITY IN PATIENTS DIAGNOSED WITH RHEUMATOID ARTHRITIS: HOW OFTEN AND TO WHAT DETAIL ARE ASSESSMENTS DOCUMENTED?**  
**Smalarz A**<sup>1</sup>, Prado M<sup>2</sup>,<sup>1</sup>Strategic Market Insight, Acton, MA, USA, <sup>2</sup>Real Health Data, Santa Cruz, CA, USA
- PMS65 K15** *pgA164* **FUNCTIONAL STATUS AMONG PATIENTS WITH RHEUMATIC DISEASES IN THE SLOVAK REPUBLIC**  
**Tomek D**<sup>1</sup>, Hroncova D<sup>2</sup>, Pechac P<sup>3</sup>,<sup>1</sup>Slovak Medical University, Bratislava, Slovak Republic, <sup>2</sup>InovaHealth Ltd., Suchohrad, Slovak Republic, <sup>3</sup>Alexander Winter Hospital Pharmacy, Piestany, Slovak Republic
- PMS66 K16** *pgA164* **SOCIO-ECONOMIC STATUS AND WORK DISABILITY AMONG PATIENTS WITH RHEUMATIC DISEASES IN THE SLOVAK REPUBLIC**  
**Tomek D**<sup>1</sup>, Hroncova D<sup>2</sup>, Pechac P<sup>3</sup>,<sup>1</sup>Slovak Medical University, Bratislava, Slovak Republic, <sup>2</sup>InovaHealth Ltd., Suchohrad, Slovak Republic, <sup>3</sup>Alexander Winter Hospital Pharmacy, Piestany, Slovak Republic

- PMS67 K17** *pgA164* **PREFERENCES FOR NEW TREATMENTS DIMINISH IN THE FACE OF AMBIGUITY**  
**Harrison M**, Bansback N, University of British Columbia, Vancouver, BC, Canada
- PMS68 K18** *pgA165* **INFILTRATION OF LIPOSOMAL BUPIVACAINE (LB) DECREASES LENGTH OF HOSPITALIZATION FOLLOWING TOTAL KNEE ARTHROPLASTY (TKA)**  
**Kirkness CS**<sup>1</sup>, Asche CV<sup>1</sup>, Ren J<sup>1</sup>, Gordon K<sup>2</sup>, Maurer P<sup>1</sup>, Maurer B<sup>3</sup>, Maurer BT<sup>4</sup>, <sup>1</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>2</sup>UnityPoint Health-Proctor, Peoria, IL, USA, <sup>3</sup>University of Illinois at Peoria, Peoria, IL, USA, <sup>4</sup>Great Plains Orthopedics, Peoria, IL, USA
- PMS69 L1** *pgA165* **PATIENT-REPORTED PHYSICAL FUNCTION OUTCOME MEASURE FOR ADULTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA: INTELLIGENT TEST DESIGN BASED ON PROMIS ITEM BANKS**  
**Mattera MS**<sup>1</sup>, Kaplan FS<sup>2</sup>, Pignolo RJ<sup>2</sup>, Grogan D<sup>3</sup>, Revicki DA<sup>1</sup>, <sup>1</sup>Evidera, Bethesda, MD, USA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>3</sup>Clementia Pharmaceuticals, Inc., Newton, MA, USA
- PMS70 L2** *pgA165* **RAPID ACQUISITION OF DATA ON THE PATIENT PERSPECTIVE IN RHEUMATOID ARTHRITIS THROUGH A DIGITAL PORTAL**  
**Cummins G**<sup>1</sup>, Goel N<sup>1</sup>, Downing J<sup>1</sup>, Tuyt Lv<sup>2</sup>, <sup>1</sup>Quintiles, Durham, NC, USA, <sup>2</sup>VU University Medical Center, Amsterdam, The Netherlands
- PMS71 L3** *pgA165* **CONTENT VALIDITY EVALUATION OF A NEW DIARY DEVELOPED TO EVALUATE SYMPTOMS IMPORTANT TO PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS**  
**DeLozier AM**<sup>1</sup>, Gaich CL<sup>1</sup>, Vernon MK<sup>2</sup>, von Maltzahn R<sup>2</sup>, <sup>1</sup>Eli Lilly, Indianapolis, IN, USA, <sup>2</sup>Evidera, London, England
- PMS72 L4** *pgA165* **DOES ORAL CHOLECALCIFEROL SUPPLEMENTATION IMPROVES PAIN INTENSITY AND DISABILITY IN PATIENTS WITH CHRONIC LOW BACK PAIN?**  
**Bansal D**<sup>1</sup>, Ghai B<sup>2</sup>, <sup>1</sup>National Institute of Pharmaceutical Education and Research, Mohali, India, <sup>2</sup>Post Graduate Institute of Medical Education and Research, Mohali, India
- PMS73 L5** *pgA165* **MINIMALLY IMPORTANT DIFFERENCES FOR PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) FATIGUE AND PAIN INTERFERENCE SCORES**  
Beaumont JL<sup>1</sup>, Fries JF<sup>2</sup>, Curtis JR<sup>3</sup>, Cella D<sup>4</sup>, **Yun H**<sup>3</sup>, <sup>1</sup>Northwestern University, Chicago, IL, USA, <sup>2</sup>Stanford University, Palo Alto, CA, USA, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL, USA, <sup>4</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- PMS74 L6** *pgA166* **OUTCOMES VALIDATION OF THE ASES, DASH, EQ5D, AND VR6D IN A POPULATION OF ORTHOPEDICS PATIENTS WITH UPPER EXTREMITY MORBIDITY**  
**Van Doren BA**, Odum SM, OrthoCarolina Research Institute, Inc., Charlotte, NC, USA
- PMS75 L7** *pgA166* **ACCUMULATED ONE YEAR HEALTH UTILITY LOSS AFTER SUSTAINING A HIP FRACTURE IN MEXICO**  
**Guirant L**<sup>1</sup>, Carlos F<sup>2</sup>, Clark P<sup>3</sup>, Curiel D<sup>3</sup>, Svedbom A<sup>4</sup>, Borgstrom F<sup>4</sup>, Kanis JA<sup>5</sup>, <sup>1</sup>Instituto Tecnológico Autónomo de México, Mexico City, Mexico, <sup>2</sup>R A C Salud Consultores S.A. de C.V, Mexico City, Mexico, <sup>3</sup>Hospital Infantil Federico Gómez- Faculty of Medicine, Mexico City, Mexico, <sup>4</sup>Karolinska Institutet, Stockholm, Sweden, <sup>5</sup>University of Sheffield Medical School, Sheffield, UK

---

#### MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies

- PMS76 L8** *pgA166* **HIGH-COST BIOLOGICS FOR RHEUMATOID ARTHRITIS: HOW ARE PAYER-LED COST-TAMING STRATEGIES IMPACTING BRAND UPTAKE IN THE UNITED STATES?**  
Cox J<sup>1</sup>, Lewis C<sup>2</sup>, **Moore R**<sup>2</sup>, <sup>1</sup>Decision Resources Group, London, UK, <sup>2</sup>Decision Resources Group, Nashville, TN, USA
- PMS77 L9** *pgA166* **BIOLOGIC BRANDS AND BIOSIMILARS FOR RHEUMATOID ARTHRITIS IN THE EU5: CONTENTION FOR COST-EFFECTIVENESS**  
**Cox J**<sup>1</sup>, Stanton C<sup>2</sup>, <sup>1</sup>Decision Resources Group, London, UK, <sup>2</sup>Decision Resources Group, Burlington, MA, USA
- PMS78 L10** *pgA166* **PATIENT, HEALTH PLAN AND COMMUNITY FACTORS ASSOCIATED WITH RECEIPT OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN MEDICARE MANAGED CARE PLANS**  
**Mehta S**, Teigland C, Pulungan Z, Kilgore K, Parente A, McClellan M, Jones B, Inovalon, Bowie, MD, USA
- PMS79 L11** *pgA167* **THE USE OF ADVANCED REPORTING INTEGRATING BIG DATA (COREREPORTS): THE CASE OF OSTEOPOROSIS**  
**Martini N**<sup>1</sup>, Maggioni AP<sup>2</sup>, Rossi E<sup>3</sup>, Esposito I<sup>1</sup>, De Rosa M<sup>3</sup>, <sup>1</sup>Accademia Nazionale di Medicina, Roma, Italy, <sup>2</sup>ANMCO Research Center, Florence, Italy, <sup>3</sup>CINECA Interuniversity Consortium, Casalecchio di Reno, Italy
- PMS80 L12** *pgA167* **PATIENT CHARACTERISTICS ASSOCIATED WITH PASSING OR FAILING THE HEDIS MEASURE FOR POST-FRACTURE OSTEOPOROSIS MANAGEMENT**  
**Vegesna A**<sup>1</sup>, Hazel-Fernandez LA<sup>2</sup>, Boytsov NN<sup>3</sup>, Saundankar V<sup>4</sup>, Yang FE<sup>3</sup>, Nair R<sup>4</sup>, Crawford AG<sup>1</sup>, McAna J<sup>1</sup>, Alatorre CI<sup>3</sup>, <sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Comprehensive Health Insights, Miramar, FL, USA, <sup>3</sup>Eli Lilly & Company, Indianapolis, IN, USA, <sup>4</sup>Comprehensive Health Insights, Louisville, KY, USA
- PMS81 L13** *pgA167* **RELATIONSHIP BETWEEN PHYSICIAN ASSESSMENT OF DISEASE SEVERITY (PER CLINICAL JUDGMENT) AND OBJECTIVE MEASURES OF DISEASE SEVERITY IN RHEUMATOID ARTHRITIS (RA): OBSERVATIONS FROM THE EUROPEAN UNION (EU) AND UNITED STATES (US)**

- Narayanan S<sup>1</sup>**, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baskett A<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS82 L14** *pgA167* **COMPARISON OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) ON DISEASE REMISSION IN THE EUROPEAN UNION (EU) AND UNITED STATES (US)**  
**Narayanan S<sup>1</sup>**, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baskett A<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS83 L15** *pgA167* **PATTERNS OF DISEASE REMISSION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC THERAPIES IN JAPAN**  
**Narayanan S<sup>1</sup>**, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baskett A<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS84 L16** *pgA167* **COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IDENTIFIED BY PHYSICIANS AS POTENTIALLY SUITABLE FOR BIOSIMILAR INFlixIMAB VERSUS THOSE WHO WERE NOT CONSIDERED BIOSIMILAR INFlixIMAB SUITABLE IN EUROPE (EU)**  
**Narayanan S<sup>1</sup>**, Lu Y<sup>2</sup>, Hutchings R<sup>2</sup>, Baskett A<sup>2</sup>, Mentzer S<sup>2</sup>,<sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, London, UK
- PMS85 L17** *pgA168* **EFFECT OF A TIER CHANGE POLICY FOR BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) ON HEALTH CARE COST AND MEDICATION EFFECTIVENESS**  
**Chastek BJ<sup>1</sup>**, Liu F<sup>1</sup>, Shah N<sup>2</sup>, Harrison DJ<sup>2</sup>,<sup>1</sup>Optum Life Sciences, Eden Prairie, MN, USA, <sup>2</sup>Amgen Inc., Thousand Oaks, CA, USA
- PMS86 L18** *pgA168* **FREQUENCY OF INCREASED MAINTENANCE DOSES OF ADALIMUMAB, ETANERCEPT, AND USTEKINUMAB**  
**Kuznik A<sup>1</sup>**, Natu A<sup>2</sup>, Siper K<sup>2</sup>, Auld M<sup>2</sup>, Gilra N<sup>2</sup>,<sup>1</sup>Celgene Corporation, Warren, NJ, USA, <sup>2</sup>ZS Associates, Princeton, NJ, USA
- PMS87 M1** *pgA168* **PERSISTENCE WITH FIRST-LINE BIOLOGICS USED IN RHEUMATOID ARTHRITIS IN A US MANAGED CARE POPULATION**  
 Gu T<sup>1</sup>, Shah N<sup>2</sup>, Deshpande G<sup>1</sup>, **Tang DH<sup>2</sup>**, Eisenberg D<sup>1</sup>, Harrison DJ<sup>2</sup>,<sup>1</sup>HealthCore Inc., Wilmington, DE, USA, <sup>2</sup>Amgen Inc., Thousand Oaks, CA, USA
- PMS88 M2** *pgA168* **ANALYSIS OF ETANERCEPT TREATMENT PATTERNS AND REIMBURSEMENT GAPS IN PATIENTS WHEN TRANSITIONING FROM PRIVATE TO PUBLIC DRUG PLANS**  
 Millson B<sup>1</sup>, Poulin-Costello M<sup>2</sup>, **Garces K<sup>2</sup>**,<sup>1</sup>IMS Brogan, Kirkland, QC, Canada, <sup>2</sup>Amgen Canada Inc., Mississauga, ON, Canada
- PMS89 M3** *pgA168* **CANADIAN PUBLIC REIMBURSEMENT OF SUBSEQUENT ENTRY BIOLOGICS (SEBS) / BIOSIMILARS**  
**Siu EC**, Wyatt G, Wyatt Health Management, Oakville, ON, Canada
- PMS90 M4** *pgA169* **IMPACT OF OVERWEIGHT/OBESITY ON ARTHRITIS-ATTRIBUTABLE BURDEN AND HEALTH-RELATED QUALITY OF LIFE AMONG ADULTS WITH ARTHRITIS**  
**Khanna R**, Joshi N, Shah R, University of Mississippi, University, MS, USA
- PMS91 M5** *pgA169* **ASSESSMENT OF OSTEOPOROSIS KNOWLEDGE AND PERCEPTION AMONG FEMALE UNIVERSITY STUDENTS IN QUETTA, PAKISTAN**  
**ul Haq N<sup>1</sup>**, Tahir M<sup>1</sup>, Iqbal Q<sup>1</sup>, Naseem A<sup>1</sup>, Mohammad S<sup>1</sup>, Ahmed N<sup>1</sup>, Azhar SA<sup>2</sup>,<sup>1</sup>University of Balochistan, Quetta, Pakistan, <sup>2</sup>COMSATS Institute of Information Technology, Abbottabad, Pakistan
- PMS92 M6** *pgA169* **THE IMPACT OF NEGATIVE TRIAL RESULTS ON THE USE OF BLOOD TRANSFUSIONS**  
**Howard DH**, Emory University, Atlanta, GA, USA

---

#### RESPIRATORY-RELATED DISORDERS - Clinical Outcomes Studies

- PRS1 M7** *pgA169* **TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) OCCURRENCE AMONG INPATIENT MEDICAID BENEFICIARIES, UNDER 65 YEARS OF AGE, AS RECORDED BY LARGE ADMINISTRATIVE DATABASES DURING 2007-2010**  
**Menis M<sup>1</sup>**, Forshee RA<sup>1</sup>, McKean S<sup>2</sup>, Warnock R<sup>2</sup>, Verma S<sup>2</sup>, Izurieta HS<sup>1</sup>, Mintz PD<sup>1</sup>, Worrall CM<sup>3</sup>, Kelman JA<sup>4</sup>, Anderson SA<sup>1</sup>,<sup>1</sup>FDA, Silver Spring, MD, USA, <sup>2</sup>Acumen LLC, Burlingame, CA, USA, <sup>3</sup>CMS, Baltimore, MD, USA, <sup>4</sup>CMS, Washington DC, DC, USA
- PRS2 M8** *pgA169* **LONG-ACTING BRONCHODILATORS AND RISK OF ADVERSE CARDIOVASCULAR EVENTS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A FOCUSED CRITICAL REVIEW**  
**Tao S<sup>1</sup>**, Kirsch E<sup>1</sup>, Yeomans K<sup>1</sup>, Sigler C<sup>2</sup>,<sup>1</sup>UBC: An Express Scripts Company, Dorval, QC, Canada, <sup>2</sup>UBC: An Express Scripts Company, Blue Bell, PA, USA
- PRS3 M9** *pgA169* **MORTALITY AND READMISSION IN MECHANICALLY VENTILATED PATIENTS WITH PNEUMONIA**  
**Hansen RN<sup>1</sup>**, Black DJ<sup>1</sup>, Joish VN<sup>2</sup>, Spilsbury-Cantalupo M<sup>2</sup>, Sullivan SD<sup>1</sup>,<sup>1</sup>University of Washington School of Pharmacy, Seattle, WA, USA, <sup>2</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA
- PRS4 M10** *pgA170* **MULTIMORBIDITY AND COPD MEDICATION RECEIPT AMONG MEDICAID BENEFICIARIES WITH NEWLY-DIAGNOSED COPD**  
**Ajmera MR<sup>1</sup>**, Sambamoorthi U<sup>2</sup>, Dwibedi N<sup>2</sup>, Rust G<sup>3</sup>,<sup>1</sup>RTI Health Solutions, RTP, NC, USA, <sup>2</sup>West Virginia University, Morgantown, WV, USA, <sup>3</sup>Morehouse School of Medicine, Atlanta, GA, USA



- PRS5 M11 pgA170 DRUG THERAPY FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**  
Canestaro WJ<sup>1</sup>, Forrester S<sup>2</sup>, Ho L<sup>1</sup>, Devine B<sup>1</sup>,<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Group Health Cooperative, Seattle, WA, USA
- PRS6 M12 pgA170 : IMPACT OF CHANGE IN LUNG FUNCTION AND COPD-RELATED PATIENT OUTCOMES ON EXACERBATIONS AND HOSPITALIZATIONS: A SYSTEMATIC LITERATURE REVIEW**  
Donohue JF<sup>1</sup>, Marvel J<sup>2</sup>, Martin AL<sup>3</sup>, Travers KU<sup>3</sup>, Cadarette S<sup>3</sup>, Wilcox TK<sup>4</sup>,<sup>1</sup>University of North Carolina, School of Medicine, Chapel Hill, NC, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>Evidera, Lexington, MA, USA, <sup>4</sup>Evidera, Castle Rock, CO, USA
- PRS7 M13 pgA170 THE USE OF HELIOX IN HOSPITALIZED CHILDREN FROM CARTAGENA COLOMBIA**  
Guzmán-Corena A<sup>1</sup>, Morales-Payares D<sup>2</sup>, Pinzón-Redondo H<sup>2</sup>, Zakzuk-Sierra J<sup>3</sup>, Orozco-Guardo M<sup>4</sup>, Aristizabal G<sup>4</sup>, Alvis-Guzman N<sup>5</sup>,<sup>1</sup>Unidad de Cuidados Intensivos "Doña Pilar". Hospital Infantil Napoleón Franco Pareja, Cartagena, Colombia, <sup>2</sup>Hospital Infantil Napoleón Franco Pareja, Cartagena., Colombia, <sup>3</sup>Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, <sup>4</sup>Unidad de Cuidados Intensivos, Cartagena, Colombia, <sup>5</sup>Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia
- PRS8 M14 pgA170 REAL-WORLD OBSERVATIONAL STUDY OF ASSOCIATION BETWEEN STATIN MEDICATIONS AND COPD-SPECIFIC OUTCOMES**  
Aimera MR<sup>1</sup>, Sambamoorthi U<sup>2</sup>, Rust G<sup>3</sup>, Pan X<sup>4</sup>, Tworek C<sup>2</sup>, Metzger A<sup>2</sup>,<sup>1</sup>RTI Health Solutions, RTP, NC, USA, <sup>2</sup>West Virginia University, Morgantown, WV, USA, <sup>3</sup>Morehouse School of Medicine, Atlanta, GA, USA, <sup>4</sup>Evidera LLC, Lexington, MA, USA
- PRS9 M15 pgA171 SELF-MEDICATION AND ASSOCIATED HEALTH CARE COSTS- A SURVEY IN THE URBAN AND RURAL POPULATION OF A MAJOR CITY IN PAKISTAN**  
Ali A, Institute of Paramedical Sciences, Karachi, Pakistan
- PRS10 M16 pgA171 MULTIFACETED INTERVENTIONS IMPROVE MEDICATION ADHERENCE AND REDUCE ACUTE HOSPITALIZATION RATES IN MEDICAID PATIENTS PRESCRIBED ASTHMA CONTROLLERS**  
Gao W<sup>1</sup>, Keleti D<sup>1</sup>, Donia T<sup>1</sup>, Downey TW<sup>1</sup>, Megargell L<sup>2</sup>, Kreitman J<sup>3</sup>, Michael KE<sup>1</sup>, Gelzer AD<sup>1</sup>,<sup>1</sup>The AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA, <sup>2</sup>PerformRx, Philadelphia, PA, USA, <sup>3</sup>AmeriHealth Caritas Pennsylvania, Harrisburg, PA, USA
- PRS11 M17 pgA171 COMPARISON ON PEDIATRIC ASTHMA HOSPITAL ADMISSIONS THROUGH EMERGENCY DEPARTMENT: MEDICAID VS PRIVATE INSURANCE**  
Wang W, Park H, University of Florida, Gainesville, FL, USA
- PRS12 M18 pgA171 MORTALITY AND REHOSPITALIZATION RATES AMONG HOSPITALIZED PNEUMONIA PATIENTS IN THE U.S. MEDICARE POPULATION**  
Li L<sup>1</sup>, Shrestha S<sup>1</sup>, Baser O<sup>2</sup>, Yuce H<sup>3</sup>, Wang L<sup>1</sup>,<sup>1</sup>STATinMED Research, Plano, TX, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, <sup>3</sup>City University of New York & STATinMED Research, New York, NY, USA
- PRS13 N1 pgA171 FACTORS AFFECTING 30-DAY HOSPITAL READMISSIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**  
Kim M<sup>1</sup>, Asche CV<sup>1</sup>, Tillis W<sup>2</sup>,<sup>1</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>2</sup>OSF Saint Francis Medical Center, Peoria, IL, USA
- PRS14 N2 pgA172 THE DETERMINANTS OF 30-DAY HOSPITAL READMISSIONS AMONG PATIENTS WITH ASTHMA**  
Kim M<sup>1</sup>, Asche CV<sup>1</sup>, Tillis W<sup>2</sup>,<sup>1</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>2</sup>OSF Saint Francis Medical Center, Peoria, IL, USA

---

#### RESPIRATORY-RELATED DISORDERS - Cost Studies

- PRS16 N3 pgA172 ECONOMIC IMPACT OF AVOIDABLE DRUG WASTAGE IN PATIENTS ADMITTED TO THE HOSPITAL FOR AN ACUTE COPD EXACERBATION**  
Bollu V<sup>1</sup>, Clark RS<sup>2</sup>, Carlton R<sup>2</sup>, Meyer KL<sup>2</sup>,<sup>1</sup>Sunovion Pharmaceuticals, Marlborough, MA, USA, <sup>2</sup>Xcenda, Palm Harbor, FL, USA
- PRS17 N4 pgA172 THE BUDGET IMPACT OF DUORESP® SPIROMAX® (BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE) COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED KINGDOM: IMPACT OF INHALATION TECHNIQUE**  
Lewis A<sup>1</sup>, Blackney M<sup>1</sup>, Torvinen S<sup>2</sup>, Plich A<sup>3</sup>,<sup>1</sup>Covance Inc., London, UK, <sup>2</sup>Teva Pharmaceuticals Europe B.V, Amsterdam, The Netherlands, <sup>3</sup>Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
- PRS18 N5 pgA172 INPATIENT VERSUS OUTPATIENT TREATMENT RELATED TO EXACERBATION EPISODES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM A PUBLIC MEXICAN INSTITUTIONAL PERSPECTIVE)**  
Huicochea-Bartelt JL<sup>1</sup>, Camacho-Cordero LM<sup>2</sup>, Herran S<sup>1</sup>,<sup>1</sup>Boehringer Ingelheim, Distrito Federal, Mexico, <sup>2</sup>Health Consultings, Distrito Federal, Mexico
- PRS19 N6 pgA172 HEALTH-CARE COSTS OF ASTHMA ARE LOWER USING MP29-02\* VS. SEQUENTIAL SPRAYS FOR ALLERGIC RHINITIS**

**Harrow B**<sup>1</sup>, Sedaghat AR<sup>2</sup>, Munzel U<sup>3</sup>, Tarr A<sup>4</sup>, Geve L<sup>1</sup>, Hofmeister J<sup>1</sup>, Dufour R<sup>4</sup>,<sup>1</sup>Meda Pharmaceuticals, Somerset, NJ, USA, <sup>2</sup>Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, MA, USA, <sup>3</sup>MEDA Pharma GmbH & Co. KG, Bad Homburg, Germany, <sup>4</sup>Comprehensive Health Insights, Inc, Louisville, KY, USA

**PRS20 N7** *pgA173* **A COST EFFICIENCY MODEL FOR COMPARING ON-DEMAND TREATMENT COSTS IN HEREDITARY ANGIOEDEMA**

**Rodino FJ**, Westra S, Churchill Outcomes Research, Maplewood, NJ, USA

**PRS21 N8** *pgA173* **COST AND RESOURCE UTILIZATION IN HOSPITAL-TREATED CAP PATIENTS**

**Tuttle EG**<sup>1</sup>, Llop CJ<sup>2</sup>,<sup>1</sup>Analysis Group, Inc, Menlo Park, CA, USA, <sup>2</sup>Analysis Group, Inc, Boston, MA, USA

**PRS22 N9** *pgA173* **OUT-OF-POCKET EXPENSES FOR COPD PATIENTS IN A THIRD LEVEL HOSPITAL**

**Martínez- Briseño D**, Fernández-Plata R, García-Sancho C, Cano-Jiménez D, Sansores-Martínez R, Ramírez-Venegas A, Casas-Medina G, National Institute of Respiratory Diseases, Mexico City, Mexico

**PRS23 N10** *pgA173* **A DESCRIPTIVE ANALYSIS OF PATIENT CHARACTERISTICS AND HEALTH CARE BURDEN ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE U.S. MEDICARE POPULATION**

**Xie L**<sup>1</sup>, Kariburyo MF<sup>1</sup>, Wang Y<sup>1</sup>, Baser O<sup>2</sup>,<sup>1</sup>STATinMED Research, Ann Arbor, MI, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

**PRS24 N11** *pgA173* **OBSERVATIONAL STUDY OF THE OUTCOMES AND COSTS OF INITIATING INHALED LONG-ACTING BRONCHODILATORS VERSUS INHALED SHORT-ACTING BRONCHODILATORS THERAPIES IN NEWLY-DIAGNOSED COPD PATIENTS**

**Lin C**, I-Shou University, Kaohsiung city, Taiwan

**PRS25 N12** *pgA173* **COST-EFFECTIVENESS OF TIOTROPIUM VS GLYCOPYRRONIUM IN MODERATE TO VERY SEVERE COPD IN CANADA, SWEDEN AND THE UK**

Eklund O<sup>1</sup>, Afzal F<sup>2</sup>, Borgström F<sup>1</sup>, Flavin J<sup>3</sup>, Ternouth A<sup>4</sup>, **Baldwin M**<sup>5</sup>,<sup>1</sup>Quantify Research AB, Stockholm, Sweden, <sup>2</sup>Boehringer Ingelheim Norway, Asker, Norway, <sup>3</sup>Boehringer Ingelheim Canada, Burlington, ON, Canada, <sup>4</sup>Boehringer Ingelheim UK, Bracknell, UK, <sup>5</sup>Boehringer Ingelheim Germany, Ingelheim, Germany

**PRS26 N13** *pgA174* **COST-EFFECTIVENESS OF REFRACTORY ASTHMA TREATMENT STRATEGIES: A DECISION TREE ANALYSIS**

**Bogart M**<sup>1</sup>, Roberts A<sup>1</sup>, Wheeler S<sup>2</sup>,<sup>1</sup>UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA, <sup>2</sup>Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**PRS27 N14** *pgA174* **COST-EFFECTIVENESS ANALYSIS OF SMOKING CESSATION INTERVENTIONS IN JAPAN USING THE DISCRETE EVENT SIMULATION MODEL**

**Igarashi A**<sup>1</sup>, Goto R<sup>2</sup>, Yoshikawa R<sup>3</sup>, Suwa K<sup>3</sup>, Ward AJ<sup>4</sup>, Moller J<sup>5</sup>,<sup>1</sup>University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, <sup>2</sup>Kyoto University, Kyoto, Japan, <sup>3</sup>Pfizer Japan Inc., Tokyo, Japan, <sup>4</sup>Evidera Inc., Lexington, MD, USA, <sup>5</sup>Evidera, London, UK

**PRS28 N15** *pgA174* **COST-MINIMIZATION ANALYSIS AND BUDGET IMPACT OF GLYCOPYRRONIUM BROMIDE VERSUS TIOTROPIUM BROMIDE AS A MAINTENANCE BRONCHODILATOR TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**

**Ruiz Miranda CI**, Ubiarco Lopez V, Chavez Plascencia E, Novartis Mexico, Mexico, Mexico

**PRS29 N16** *pgA174* **LOSS OF PRODUCTIVITY COSTS ATTRIBUTABLE TO BEING OVERWEIGHT OR OBESE IN WORKING ASTHMA PATIENTS IN THE US**

**Lee S**<sup>1</sup>, Chang C<sup>1</sup>, Kim C<sup>2</sup>, Lee SR<sup>1</sup>, Suh D<sup>1</sup>,<sup>1</sup>Chung-Ang University, Seoul, South Korea, <sup>2</sup>Catholic University College of Medicine, Seoul, South Korea

**PRS30 N17** *pgA174* **ECONOMIC BURDEN OF CHRONIC SPONTANEOUS URTICARIA AND PSORIASIS: PATIENTS PERSPECTIVE FROM EUROPE & US**

**Tian H**<sup>1</sup>, Gabriel S<sup>1</sup>, Balp M<sup>2</sup>, Karagiannis T<sup>3</sup>, Vietri J<sup>4</sup>,<sup>1</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>2</sup>Novartis Pharma AG, Basel, Switzerland, <sup>3</sup>Jefferson School of Population Health for Novartis Pharmaceuticals, East Hanover, NJ, USA, <sup>4</sup>Kantar Health, Horsham, PA, USA

**PRS31 N18** *pgA174* **ASSURE-CSU CANADIAN RESULTS: ASSESSING THE IMPACT OF CHRONIC SPONTANEOUS /IDIOPATHIC URTICARIA ON WORK PRODUCTIVITY AND INDIRECT COSTS**

Sussman G<sup>1</sup>, Lee J<sup>1</sup>, **Chiva-Razavi S**<sup>2</sup>, Chambenoit O<sup>2</sup>, Hollis K<sup>3</sup>, McBride D<sup>4</sup>, Westlund R<sup>5</sup>, Tian H<sup>6</sup>, Balp M<sup>7</sup>,<sup>1</sup>University of Toronto, Toronto, ON, Canada, <sup>2</sup>Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, <sup>3</sup>RTI Solutions, North Carolina, NC, USA, <sup>4</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>5</sup>RTI Solutions, Research Triangle Park, NC, USA, <sup>6</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>7</sup>Novartis Pharma AG, Basel, Switzerland

**PRS32 O1** *pgA175* **COST-CONSEQUENCE OF EOSINOPHILIC ASTHMA AMONG PATIENTS TREATED ACCORDING TO ERS/ATS GUIDELINES**

**Casciano J**<sup>1</sup>, Krishnan J<sup>2</sup>, Buatti-Small M<sup>3</sup>, Li C<sup>4</sup>, Dotiwala Z<sup>1</sup>,<sup>1</sup>eMAX Health Systems LLC., White Plains, NY, USA, <sup>2</sup>University of Illinois Hospital and Health Sciences System, Chicago, IL, USA, <sup>3</sup>Teva, Frazer, PA, USA, <sup>4</sup>University of Arkansas for Medical Sciences, Little Rock, AR, USA

---

## RESPIRATORY-RELATED DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

**PRS34 O2** *pgA175* **PATIENT PREFERENCE FOR REAL-TIME FEEDBACK IN EPRO ASSESSMENTS FOR COPD CLINICAL TRIALS**

**Khurana L**<sup>1</sup>, Gary ST<sup>1</sup>, Vazquez V<sup>1</sup>, Otero A<sup>1</sup>, Evans C<sup>2</sup>, Dallabrida S<sup>1</sup>,<sup>1</sup>PHT Corporation, Boston, MA, USA, <sup>2</sup>Endpoint Outcomes, Boston, MA, USA

**PRS35 O3 pgA175 ASSURE-CSU CANADIAN RESULTS: ASSESSING HEALTH UTILITY IN CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA USING THE EQ-5D**

Sussman G<sup>1</sup>, Waserman S<sup>2</sup>, Keith P<sup>2</sup>, **Chiva-Razavi S**<sup>3</sup>, Chambenoit O<sup>3</sup>, Hollis K<sup>4</sup>, McBride D<sup>5</sup>, Westlund R<sup>4</sup>, Tian H<sup>6</sup>, Balp M<sup>7</sup>,<sup>1</sup>University of Toronto, Toronto, ON, Canada, <sup>2</sup>Department of Medicine, Hamilton, ON, Canada, <sup>3</sup>Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, <sup>4</sup>RTI Solutions, Research Triangle Park, NC, USA, <sup>5</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>6</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>7</sup>Novartis Pharma AG, Basel, Switzerland

**PRS36 O4 pgA175 IMPACT OF PHARMACISTS-LED INTERVENTIONS TO ASSESS KNOWLEDGE, ATTITUDE AND PERCEPTION AMONG TUBERCULOSIS PATIENTS IN PAKISTAN: AN INSIGHT FROM A RANDOMIZED CONTROLLED NON CLINICAL TRIAL**

**Iqbal MS**<sup>1</sup>, Iqbal MZ<sup>2</sup>, Iqbal MW<sup>3</sup>, Bahari MB<sup>4</sup>, Nasir S<sup>5</sup>,<sup>1</sup>Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, <sup>2</sup>Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, <sup>3</sup>Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, <sup>4</sup>Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, <sup>5</sup>Nishtar Hospital, Multan, Pakistan

**PRS37 O5 pgA175 TREATMENT OUTCOMES OF SMEAR POSITIVE PULMONARY TB CASES REGISTERED IN TB PATIENTS IN QUETTA**

**ul Haq N**<sup>1</sup>, Baloch W<sup>1</sup>, Iqbal Q<sup>1</sup>, Naseem A<sup>1</sup>, Bashir S<sup>2</sup>,<sup>1</sup>University of Balochistan, Quetta, Pakistan, <sup>2</sup>University of Sargodha, Sargodha, Pakistan

**PRS38 O6 pgA176 THE IMPACT OF EMOTIONAL AND SOCIAL SUPPORT ON THE QUALITY OF LIFE, DEPRESSION, AND DISABILITY AMONG US ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISORDER (COPD): A PROPENSITY SCORE ANALYSIS**

**Arabyat R**<sup>1</sup>, Raisch DW<sup>2</sup>,<sup>1</sup>University of New Mexico College of Pharmacy, Albuquerque, NM, USA, <sup>2</sup>University of New Mexico, Albuquerque, NM, USA

**PRS39 O7 pgA176 HUMANISTIC BURDEN OF CHRONIC SPONTANEOUS URTICARIA IN COMPARISON TO PSORIASIS: US AND EUROPEAN PERSPECTIVE**

**Tian H**<sup>1</sup>, Vietri J<sup>2</sup>, Gabriel S<sup>1</sup>, Karagiannis T<sup>3</sup>, Balp M<sup>4</sup>,<sup>1</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>2</sup>Kantar Health, Horsham, PA, USA, <sup>3</sup>Jefferson School of Population Health for Novartis Pharmaceuticals, East Hanover, NJ, USA, <sup>4</sup>Novartis Pharma AG, Basel, Switzerland

**PRS40 O8 pgA176 WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT ACROSS NINETEEN MEDICAL CONDITIONS IN A REPRESENTATIVE SAMPLE OF US ADULTS**

**Witt EA**<sup>1</sup>, DiBonaventura MD<sup>2</sup>,<sup>1</sup>Kantar Health, Princeton, NJ, USA, <sup>2</sup>Kantar Health, New York, NY, USA

**PRS41 O9 pgA176 A REVIEW OF HEALTH-RELATED QUALITY OF LIFE (HRQL) CLAIMS IN LABELS OF ASTHMA PRODUCTS – CAN WE CONSIDER THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) AS A POTENTIALLY ACCEPTABLE MEASURE FOR QUALIFICATION?**

**Acquadro C**<sup>1</sup>, Conway K<sup>1</sup>, Juniper EF<sup>2</sup>, Perret C<sup>1</sup>,<sup>1</sup>Mapi Research Trust, Lyon, France, <sup>2</sup>McMaster University, Hamilton, ON, Canada

**PRS42 P1 pgA176 RELATIONSHIP BETWEEN HEALTH-RELATED INTERNET ACTIVITIES AND HEALTH-RELATED QUALITY OF LIFE AMONG ASTHMA PATIENTS**

**Kanchanasuwan S**, Wang Y, Young HN,<sup>1</sup>University of Georgia, Athens, GA, USA

**PRS44 P3 pgA177 AN EVALUATION OF SMOKERS' PREFERENCE FOR CHARACTERISTICS OF TOBACCO CESSATION MEDICATIONS: A WILLINGNESS TO PAY APPROACH**

**Xu X**<sup>1</sup>, Dube SR<sup>2</sup>, Pesko MF<sup>3</sup>,<sup>1</sup>Centers for Disease Control and Prevention, Atlanta, GA, USA, <sup>2</sup>Georgia State University, Atlanta, GA, USA, <sup>3</sup>WEILL CORNELL MEDICAL COLLEGE, New York, NY, USA

---

**RESPIRATORY-RELATED DISORDERS - Health Care Use & Policy Studies**

**PRS45 P4 pgA177 DESCRIBING TREATMENT PATTERNS IN ADOLESCENTS AND ADULTS WITH ALLERGIC ASTHMA**

**Gabriel S**<sup>1</sup>, Karagiannis T<sup>2</sup>, Li Y<sup>3</sup>, Zhou H<sup>4</sup>, Herrera V<sup>1</sup>, Russo P<sup>5</sup>,<sup>1</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>2</sup>Jefferson School of Population Health for Novartis Pharmaceuticals, East Hanover, NJ, USA, <sup>3</sup>Novartis Pharmaceuticals, East Hanover, NJ, USA, <sup>4</sup>KmK Consulting Inc. for Novartis Pharmaceuticals, Florham Park, NJ, USA, <sup>5</sup>DataMedSolutions, Washington, DC, USA

**PRS46 P5 pgA177 IMPROVED HEALTH CARE OUTCOMES AND COST SAVINGS FOR ASTHMA THROUGH TARGETED HOME INTERVENTIONS**

**Norlien KG**<sup>1</sup>, Carlson AM<sup>2</sup>, York PV<sup>1</sup>,<sup>1</sup>Minnesota Department of Health, St. Paul, MN, USA, <sup>2</sup>Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

**PRS47 P6 pgA177 THE EFFECT OF INTRODUCTION OF GENERIC DRUGS ON PATIENTS' ACCESS TO PHARMACEUTICALS IN HUNGARY**

Répásky B<sup>1</sup>, Endrei D<sup>1</sup>, Csákvári T<sup>2</sup>, Vajda R<sup>1</sup>, Danku N<sup>1</sup>, **Boncz I**<sup>1</sup>,<sup>1</sup>University of Pécs, Pécs, Hungary, <sup>2</sup>University of Pécs, Zalaegerszeg, Hungary

**PRS48 P7** *pgA177* **ADHERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE MAINTENANCE MEDICATION AMONG PATIENTS WITH COPD**

**Zhang S**, Thomas III J, Purdue University, West Lafayette, IN, USA

**PRS49 P8** *pgA178* **THE EARLY IMPACT OF CLOSING THE COVERAGE GAP ON ANNUAL DRUG EXPENDITURES, OUT-OF-POCKET SPENDING, DRUG UTILIZATION, AND ACCESS TO PRESCRIPTION AMONG SENIORS WITH CHRONIC CONDITIONS**

**Bonakdar A**, Virginia Commonwealth University, Richmond, VA, USA

**PRS50 P9** *pgA178* **REIMBURSEMENT AND PRESCRIBING IN EXCHANGE-BASED PLANS: HOW DOES FORMULARY GENEROSITY DIFFER FROM COMMERCIAL PLANS AND IS INDICATION A KEY FACTOR?**

**Moore R**, Lewis C, Decision Resources Group, Nashville, TN, USA

**PRS51 Q1** *pgA178* **RETURN ON INVESTMENT OF SMOKING CESSATION BENEFIT COMPARISON IN GUANGDONG, CHINA**

**Liu D**<sup>1</sup>, Zhu S<sup>2</sup>, Dong P<sup>1</sup>,<sup>1</sup>Pfizer Investment Co., Ltd., Beijing, China, <sup>2</sup>Shenyang Pharmaceutical University, Shenyang, China

**PRS52 Q2** *pgA178* **AVAILABILITY AND USE OF EPINEPHRINE AUTO-INJECTORS FOR THE TREATMENT OF ANAPHYLAXIS: RESULTS FROM THE EPIPEN4SCHOOLS® SURVEY**

**Hogue S**<sup>1</sup>, Bennett ME<sup>2</sup>, Goss D<sup>1</sup>, Hollis K<sup>3</sup>, Millar KE<sup>1</sup>, Silvia S<sup>1</sup>, Siegel PH<sup>1</sup>, Wolf R<sup>4</sup>, Wooddell M<sup>4</sup>, White MV<sup>5</sup>,<sup>1</sup>RTI International, Research Triangle Park, NC, USA, <sup>2</sup>Clarity Consulting, LLC, Raleigh, NC, USA, <sup>3</sup>RTI Solutions, Research Triangle Park, NC, USA, <sup>4</sup>Mylan Specialty LP, Canonsburg, PA, USA, <sup>5</sup>Institute for Asthma & Allergy, Wheaton, MD, USA

**PRS53 Q3** *pgA178* **ASSESSMENT OF DISEASE STATE KNOWLEDGE AMONG TB PATIENTS IN QUETTA, PAKISTAN**

**ul Haq N**, Kakar P, Iqbal Q, Naseem A, Baloch M, Arsalan M, University of Balochistan, Quetta, Pakistan

---

### **SENSORY SYSTEMS DISORDERS - Clinical Outcomes Studies**

**PSS1 Q4** *pgA178* **RATE OF ADVERSE EVENT-RELATED TREATMENT CHANGES AND HEALTHCARE COSTS ASSOCIATED WITH TOPICAL ROSACEA TREATMENT**

**Williamson T**<sup>1</sup>, Kamalakar R<sup>1</sup>, Ogonnaya A<sup>2</sup>, Kish J<sup>2</sup>, Zagadailov EA<sup>2</sup>, Eaddy M<sup>2</sup>, Kreilick C<sup>1</sup>,<sup>1</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>Xcenda, Palm Harbor, FL, USA

**PSS2 Q5** *pgA179* **INDIRECT TREATMENT COMPARISON OF INTERVENTIONS FOR NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (WET AMD)**

**Malcolm WA**<sup>1</sup>, Hodgson R<sup>2</sup>, Glanville J<sup>2</sup>, Barata T<sup>3</sup>, Fleetwood K<sup>3</sup>,<sup>1</sup>Novartis UK, Frimley, UK, <sup>2</sup>York Health Economics Consortium, York, UK, <sup>3</sup>Quantics Consulting Ltd, Edinburgh, UK

**PSS3 Q6** *pgA179* **COMPARATIVE EFFECTIVENESS OF BIMATOPROST 0.03%/TIMOLOL 0.5% PRESERVATIVE-FREE FIXED COMBINATION FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OHT; INTERPRETING RESULTS FROM A LARGE TREATMENT NETWORK**

**Saunders O**<sup>1</sup>, Wong W<sup>2</sup>, Collomb D<sup>3</sup>, Stradwick S<sup>1</sup>,<sup>1</sup>BresMed, Sheffield, UK, <sup>2</sup>Allergan Inc, Irvine, CA, USA, <sup>3</sup>Allergan Ltd, Marlow, UK

**PSS4 Q7** *pgA179* **EFFICACY OF SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS: AREA UNDER THE CURVE OF TREATMENT RESPONSE RATES**

**Armstrong AW**<sup>1</sup>, Feldman SR<sup>2</sup>, Korman NJ<sup>3</sup>, Meng X<sup>4</sup>, Guana A<sup>4</sup>, Nyirady J<sup>4</sup>, Herrera V<sup>4</sup>, Zhao Y<sup>4</sup>,<sup>1</sup>University of Colorado Denver School of Medicine, Aurora, CO, USA, <sup>2</sup>Wake Forest University School of Medicine, Winston-Salem, NC, USA, <sup>3</sup>University Hospitals Case Medical Center, Cleveland, OH, USA, <sup>4</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

**PSS5 Q8** *pgA179* **KNOWLEDGE AND PRACTICE OF PHARMACY STUDENTS REGARDING THE USE OF SKIN WHITENING PRODUCT**

**Ab Hadi H**, Awadh A, International Islamic University Malaysia, Kuantan, Malaysia

**PSS6 Q9** *pgA179* **ANTIDEPRESSANT USE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION AND DEPRESSIVE SYMPTOMS: BASELINE RESULTS FROM THE LOW VISION DEPRESSION PREVENTION TRIAL**

**Pizzi LT**<sup>1</sup>, Karel LI<sup>2</sup>, Shang T<sup>1</sup>, Casten RJ<sup>3</sup>, Rovner BW<sup>4</sup>,<sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Thomas Jefferson University Hospital, Philadelphia, PA, USA, <sup>3</sup>Jefferson Hospital for Neuroscience, Philadelphia, PA, USA, <sup>4</sup>Jefferson Hospital for Neuroscience, Philadelphia, PA, USA

**PSS7 R1** *pgA179* **STUDY OF PSYCHOLOGICAL STRESS AND ACNE VULGARIS AMONG PHARMACY STUDENTS**

**Ab Hadi H**, Awadh A, International Islamic University Malaysia, Kuantan, Malaysia

**PSS8 R2** *pgA180* **USE OF CONSUMER MARKET RESEARCH PANELS TO GENERATE PREVALENCE AND DISEASE BURDEN ESTIMATES IN DATA-SPARSE DISEASES: A CASE STUDY IN SEVERE CHRONIC HAND ECZEMA**

Elder E<sup>1</sup>, Nathan M<sup>1</sup>, Piggott S<sup>1</sup>, Soorkia R<sup>2</sup>, Scrutton C<sup>2</sup>, Turner G<sup>2</sup>, **Pomerantz D**<sup>3</sup>,<sup>1</sup>Stiefel, Brentford, UK, <sup>2</sup>Kantar Health, Epsom, UK, <sup>3</sup>Kantar Health, Horsham, PA, USA

**PSS9 R3** *pgA180* **THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION IN INDIAN POPULATION: A SYSTEMATIC REVIEW**

Likhar N, Mothe RK, Kanukula R, Shah C, **Dang A**, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

---

### **SENSORY SYSTEMS DISORDERS - Cost Studies**



- PSS10 R4** *pgA180* **A FIRST STUDY TO DETERMINE THE ECONOMIC IMPACT OF DENTAL CAVITIES IN COLOMBIA FOR 2011**  
**Robles A**, Upegui A, Simbaqueba E, Zarama P, Unicoc University, Bogota, Colombia
- PSS11 R5** *pgA180* **RECENT COST TRENDS IN PATIENTS USING BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS**  
**Kuznik A**<sup>1</sup>, Eslava S<sup>2</sup>, Cai J<sup>3</sup>,<sup>1</sup>Celgene Corporation, Warren, NJ, USA, <sup>2</sup>Celgene Corporation, Berkeley Heights, NJ, USA, <sup>3</sup>Celgene Corporation, Summit, NJ, USA
- PSS12 R6** *pgA180* **INJECTION FREQUENCY AND COSTS OF ANTI-VEGF TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, RETINAL VEIN OCCLUSION, AND DIABETIC MACULAR EDEMA**  
**Turpcu A**<sup>1</sup>, Wilson K<sup>2</sup>, Huang A<sup>2</sup>, Smith DM<sup>2</sup>, Varker H<sup>2</sup>, Johnston S<sup>2</sup>,<sup>1</sup>Genentech, Inc., South San Francisco, CA, USA, <sup>2</sup>Truven Health Analytics, Bethesda, MD, USA
- PSS13 R7** *pgA180* **ESTIMATING THE PREVALENCE OF EQUINE RECURRENT UVEITIS AND THE ASSOCIATED LOSS OF VALUE FROM VISUAL IMPAIRMENT IN HORSES IN THE UNITED STATES**  
Poulsen Nautrup B<sup>1</sup>, Van Vlaenderen I<sup>2</sup>, Holland R<sup>3</sup>, **Donecker JM**<sup>3</sup>,<sup>1</sup>EAH-Consulting, Aachen, Germany, <sup>2</sup>CHESS BVBA, Ternat, Belgium, <sup>3</sup>Zoetis, Florham Park, NJ, USA
- PSS14 R8** *pgA181* **COST OF ILLNESS, DIAGNOSIS AND TREATMENT PATTERNS FOR DIABETIC MACULAR EDEMA ACROSS 13 COUNTRIES**  
McLeod E<sup>1</sup>, Lovato E<sup>2</sup>, Wittrup-Jensen KU<sup>3</sup>, **Muston DR**<sup>4</sup>,<sup>1</sup>Pfizer Ltd, Surrey, UK, <sup>2</sup>IMS Health, London, UK, <sup>3</sup>Bayer Pharma AG, Berlin, Germany, <sup>4</sup>Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ, USA
- PSS15 R9** *pgA181* **COMPARING TOTAL AND DISEASE SPECIFIC HEALTHCARE COSTS FOR GLAUCOMA PATIENTS BEFORE AND AFTER THEIR INDEX DIAGNOSIS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS**  
**Yep T**<sup>1</sup>, Patel V<sup>1</sup>, Slejko JF<sup>2</sup>, Devine B<sup>3</sup>,<sup>1</sup>Allergan, Inc, Irvine, CA, USA, <sup>2</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA, <sup>3</sup>University of Washington, Seattle, WA, USA
- PSS16 S1** *pgA181* **ESTIMATING THE TREATMENT COSTS FOR PATIENTS WITH CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA IN TAIWAN**  
**Tang C**<sup>1</sup>, Chu C<sup>2</sup>, Cho Y<sup>2</sup>, Jiang J<sup>1</sup>, Lin EI<sup>3</sup>,<sup>1</sup>Taipei Medical University, Taipei, Taiwan, <sup>2</sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>3</sup>Novartis Taiwan, Taipei, Taiwan
- PSS17 S2** *pgA181* **TITLE: COST OF CANALICULAR LACERATION REPAIR IN DIFFERENT HOSPITAL SETTINGS: A DECISION ANALYSIS**  
**Cannon-Dang E**<sup>1</sup>, Murchison AP<sup>2</sup>, Bilyk JR<sup>2</sup>, Pizzi LT<sup>1</sup>,<sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Wills Eye Hospital, Philadelphia, PA, USA
- PSS18 S3** *pgA181* **COST-EFFECTIVENESS OF AFLIBERCEPT IN THE TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION IN TURKEY**  
Tunalioglu A<sup>1</sup>, Ozdemir O<sup>2</sup>, Eldem B<sup>3</sup>, Unlu N<sup>4</sup>, Alp MN<sup>5</sup>, Saatci AO<sup>6</sup>, Ozmert E<sup>7</sup>, **Deger C**<sup>8</sup>, Asan S<sup>1</sup>, Sumer F<sup>8</sup>, Parali E<sup>1</sup>, Ozel MO<sup>1</sup>, Erdal E<sup>1</sup>, Sar C<sup>1</sup>,<sup>1</sup>Bayer Turk Kimya San. Ltd. Sti, Istanbul, Turkey, <sup>2</sup>Yorum Consultancy, Istanbul, Turkey, <sup>3</sup>Hacettepe University Faculty of Medicine, Ankara, Turkey, <sup>4</sup>Ankara Training & Research Hospital, Ankara, Turkey, <sup>5</sup>Ankara Numune Training & Research Hospital, Ankara, Turkey, <sup>6</sup>Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, <sup>7</sup>Ankara University, Faculty of Medicine, Ankara, Turkey, <sup>8</sup>Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey
- PSS19 S4** *pgA182* **COST-EFFECTIVENESS OF SECUKINUMAB COMPARED TO CURRENT TREATMENTS FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN CANADA**  
Lee A<sup>1</sup>, **Gregory V**<sup>2</sup>, Gu Q<sup>3</sup>, Becker DL<sup>1</sup>, Barbeau M<sup>2</sup>,<sup>1</sup>Optum, Burlington, ON, Canada, <sup>2</sup>Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, <sup>3</sup>Optum, Waltham, MA, USA
- PSS20 S5** *pgA182* **COST ANALYSIS OF THE PHILADELPHIA GLAUCOMA COMMUNITY DETECTION AND TREATMENT PROJECT**  
**Pizzi LT**<sup>1</sup>, Steele D<sup>1</sup>, Sembhi H<sup>2</sup>, Hark L<sup>2</sup>, Waisbourd M<sup>2</sup>, Katz LJ<sup>2</sup>,<sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Wills Eye Hospital, Philadelphia, PA, USA
- PSS21 S6** *pgA182* **COST-EFFECTIVENESS OF AFLIBERCEPT IN THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION IN TURKEY**  
Tunalioglu A<sup>1</sup>, Ozdemir O<sup>2</sup>, Eldem B<sup>3</sup>, Unlu N<sup>4</sup>, Alp MN<sup>5</sup>, Saatci AO<sup>6</sup>, Ozmert E<sup>7</sup>, **Deger C**<sup>1</sup>, Asan S<sup>1</sup>, Sumer F<sup>1</sup>, Parali E<sup>1</sup>, Ozel MO<sup>1</sup>, Erdal E<sup>1</sup>, Sar C<sup>1</sup>,<sup>1</sup>Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, <sup>2</sup>Yorum Consultancy Ltd., Istanbul, Turkey, <sup>3</sup>Hacettepe University Faculty of Medicine, Ankara, Turkey, <sup>4</sup>Ankara Training & Research Hospital, Ankara, Turkey, <sup>5</sup>Ankara Numune Training & Research Hospital, Ankara, Turkey, <sup>6</sup>Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, <sup>7</sup>Ankara University, Faculty of Medicine, Ankara, Turkey
- PSS22 S7** *pgA182* **COST-EFFECTIVENESS OF IKERVIS® IN SEVERE DRY EYE DISEASE IN THE UK**  
**Ernst F**<sup>1</sup>, Morton T<sup>2</sup>, Thompson J<sup>2</sup>, Eaton J<sup>2</sup>, Mealing S<sup>2</sup>, Hawkins NS<sup>3</sup>, Amrane M<sup>1</sup>,<sup>1</sup>Santen Pharmaceutical, Munich, Germany, <sup>2</sup>Icon, Dublin, Germany, <sup>3</sup>ICON PLC, Oxford, UK
- PSS23 S8** *pgA182* **COST EFFECTIVENESS OF ANTIGLAUCOMA MEDICATIONS**  
**Usifoh SE**, UNIVERSITY OF BENIN,, BENIN, Nigeria
- PSS25 T1** *pgA183* **AN ECONOMIC EVALUATION OF RANIBIZUMAB VERSUS AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR (WET) AMD IN THE UNITED KINGDOM**  
**Malcolm WA**<sup>1</sup>, Claxton L<sup>2</sup>, Hodgson R<sup>3</sup>, Taylor M<sup>2</sup>,<sup>1</sup>Novartis UK, Frimley, UK, <sup>2</sup>York Health Economics Consortium, University of York, York, UK, <sup>3</sup>York Health Economics Consortium, York, UK

**PSS26 T2** *pgA183* **ESTIMATING COST-EFFECTIVE DEVICE PRICES FOR PEDIATRIC COCHLEAR IMPLANTATION IN INDIA**  
**Drennan WR**, Banerjee S, Garrison L, University of Washington, Seattle, WA, USA

---

**SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient Preference Studies**

- PSS27 T3** *pgA183* **DIAGNOSTIC DELAY IN PATIENTS DIAGNOSED WITH CUTANEOUS MALIGNANT MELANOMA**  
Horváthné Kívés Z<sup>1</sup>, **Boncz I**<sup>1</sup>, Gyuró M<sup>1</sup>, Vajda R<sup>1</sup>, Sándor J<sup>2</sup>,<sup>1</sup>University of Pécs, Pécs, Hungary, <sup>2</sup>University of Debrecen, Debrecen, Hungary
- PSS28 T4** *pgA183* **MEASUREMENT PROPERTIES OF THE PATIENT-REPORTED PSORIASIS SYMPTOM INVENTORY DAILY DIARY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS**  
Viswanathan HN<sup>1</sup>, **Mutebi A**<sup>1</sup>, Milmont CE<sup>1</sup>, Gordon K<sup>2</sup>, Wilson H<sup>3</sup>, Zhang H<sup>1</sup>, Klekotka P<sup>1</sup>, Revicki DA<sup>4</sup>, Augustin M<sup>5</sup>, Kricorian G<sup>1</sup>, Nirula A<sup>1</sup>, Strober B<sup>6</sup>,<sup>1</sup>Amgen, Thousand Oaks, CA, CA, USA, <sup>2</sup>Northwestern University, Chicago, IL, USA, <sup>3</sup>Evidera, Seattle, WA, USA, <sup>4</sup>Evidera, Bethesda, MD, USA, <sup>5</sup>University Medical Center Hamburg-Eppendorf, Hamburg, Germany, <sup>6</sup>University of Connecticut, Farmington, CT, USA
- PSS29 T5** *pgA183* **MEASURING DISEASE SPECIFIC IMPACT AND SYMPTOMS AMONG PATIENTS WITH HIDRADENITIS SUPPURATIVA**  
**Kimball A**<sup>1</sup>, Sundaram M<sup>2</sup>, Mathias A<sup>3</sup>, Foley C<sup>3</sup>, Shields A<sup>3</sup>,<sup>1</sup>Harvard Medical School, Boston, MA, USA, <sup>2</sup>AbbVie Inc., North Chicago, IL, USA, <sup>3</sup>Adelphi Values USA, Boston, MA, USA
- PSS30 T6** *pgA184* **SENSITIVITY OF FUNCTIONAL READING INDEPENDENCE (FRI) INDEX TO CHANGE IN SIZE OF GEOGRAPHIC ATROPHY**  
**Kapre AW**<sup>1</sup>, Kimel M<sup>2</sup>, Bressler N<sup>3</sup>, Varma R<sup>4</sup>, Souied EH<sup>5</sup>, Dolan C<sup>6</sup>, Tschosik E<sup>1</sup>, Leidy N<sup>2</sup>,<sup>1</sup>Genentech, South San Francisco, CA, USA, <sup>2</sup>Evidera, Bethesda, MD, USA, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>4</sup>USC Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, <sup>5</sup>Centre Hospitalier Intercommunal, University Paris Est, CRC, Créteil, France, <sup>6</sup>CMD Consulting, Inc., Sandy, UT, USA
- PSS31 T7** *pgA184* **DEMONSTRATING CONCEPTUAL EQUIVALENCE: TRANSLATION OF THE URTICARIA ACTIVITY AND IMPACT MEASURE (U-AIM) FROM ENGLISH INTO SPANISH**  
**Parks-Vernizzi E**<sup>1</sup>, Antonova EN<sup>2</sup>, Arnold B<sup>1</sup>, Perez B<sup>1</sup>, Zazzali JL<sup>2</sup>,<sup>1</sup>FACITtrans, Elmhurst, IL, USA, <sup>2</sup>Genentech, Inc., South San Francisco, CA, USA
- PSS32 T8** *pgA184* **PATIENT REPORTED OUTCOMES IN GLAUCOMA A SYSTEMATIC REVIEW**  
**Aggarwal S**<sup>1</sup>, Topaloglu H<sup>1</sup>, Kumar S<sup>2</sup>,<sup>1</sup>NOVEL Health Strategies, Chevy Chase, MD, USA, <sup>2</sup>GLOBAL ACCESS Monitor, Bethesda, MD, USA
- PSS33 T9** *pgA184* **BENEFITS OF PATIENT-REPORTED OUTCOMES IN DERMATOLOGY DRUG DEVELOPMENT**  
**Copleymerriman C**<sup>1</sup>, Zelt S<sup>2</sup>, Clark M<sup>1</sup>, Gnanasakthy A<sup>3</sup>,<sup>1</sup>RTI Health Solutions, Ann Arbor, MI, USA, <sup>2</sup>GlaxoSmithKline, Research Triangle Park, MI, USA, <sup>3</sup>RTI Health Solutions, Research Triangle Park, NC, USA
- PSS34 U1** *pgA184* **RASCH ANALYSIS OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR PSORIASIS TREATMENT (PROMPT)**  
**Kitchen H**<sup>1</sup>, Cordingley L<sup>2</sup>, Gibbons C<sup>2</sup>, Young H<sup>3</sup>, Griffiths CE<sup>3</sup>, Bundy C<sup>2</sup>,<sup>1</sup>Abacus International, Manchester, UK, <sup>2</sup>University of Manchester and Manchester Academic Health Science Centre, Manchester, UK, <sup>3</sup>University of Manchester and Manchester Academic Health Science Centre and Salford Royal NHS Foundation Trust, Salford, UK
- PSS35 U2** *pgA184* **CONTENT DEVELOPMENT AND REFINEMENT FOR A NEW PATIENT REPORTED OUTCOME MEASURE FOR PSORIASIS TREATMENT (PROMPT)**  
**Kitchen H**<sup>1</sup>, Cordingley L<sup>2</sup>, Young H<sup>3</sup>, Griffiths CE<sup>3</sup>, Bundy C<sup>2</sup>,<sup>1</sup>Abacus International, Manchester, UK, <sup>2</sup>University of Manchester and Manchester Academic Health Science Centre, Manchester, UK, <sup>3</sup>University of Manchester and Manchester Academic Health Science Centre and Salford Royal NHS Foundation Trust, Salford, UK
- PSS36 U3** *pgA185* **CLIENT ACCEPTANCE TRIAL WITH INJECTABLE CEFOVECIN SODIUM IN DOGS AS A FIRST LINE OF TREATMENT FOR SUPERFICIAL PYODERMA, WOUNDS, AND ABSCESES CAUSED BY SUSCEPTIBLE STRAINS OF STAPHYLOCOCCUS INTERMEDIUS AND STREPTOCOCCUS CANIS GROUP G**  
**Wright AK**<sup>1</sup>, Russo S<sup>2</sup>, DiFranco B<sup>2</sup>, Gasper S<sup>2</sup>, Amodie D<sup>2</sup>,<sup>1</sup>Zoetis, Greeley, CO, USA, <sup>2</sup>Zoetis, Florham Park, NJ, USA
- PSS37 U4** *pgA185* **AVAILABILITY AND AFFORDABILITY OF ANTIGLAUCOMA DRUGS IN BENIN CITY, NIGERIA**  
**Usifoh SE**, UNIVERSITY OF BENIN,, BENIN, Nigeria

---

**SENSORY SYSTEMS DISORDERS - Health Care Use & Policy Studies**

- PSS38 U5** *pgA185* **A RETROSPECTIVE COHORT STUDY TO INVESTIGATE ACTUAL TREATMENT FOR GLAUCOMA USING A JAPANESE HEALTHCARE DATABASE**  
**Sugimoto N**<sup>1</sup>, Kawai N<sup>1</sup>, Yoshiyama T<sup>1</sup>, Yamamoto Y<sup>2</sup>, Yamazaki T<sup>2</sup>, Shirai C<sup>1</sup>, Fujimoto Y<sup>1</sup>,<sup>1</sup>Pfizer Japan Inc, Tokyo, Japan, <sup>2</sup>MinaCare co.ltd, Tokyo, Japan
- PSS39 U6** *pgA185* **ASSESSING THE IMPACT OF INCREASED MAINTENANCE DOSING OF ADALIMUMAB AND ETANERCEPT ON MANAGED CARE COSTS**  
**Kuznik A**<sup>1</sup>, Natsu A<sup>2</sup>, Siper K<sup>2</sup>, Auld M<sup>2</sup>, Gilra N<sup>2</sup>,<sup>1</sup>Celgene Corporation, Warren, NJ, USA, <sup>2</sup>ZS Associates, Princeton, NJ, USA
- PSS40 U7** *pgA185* **UTILIZATION, PRICE, AND SPENDING TRENDS FOR FLUOROQUINOLONES IN THE US MEDICAID PROGRAM: 1991-2013**

Yue X, Guo JJ, Xia Y, Almalki ZS, Wigle PR, University of Cincinnati, Cincinnati, OH, USA

**PSS41 V1 pgA186 ASSOCIATION OF OBESITY WITH 30-DAY READMISSION RATES AMONG PATIENTS HOSPITALIZED WITH ACUTE BACTERIAL SKIN AND SKIN-STRUCTURE INFECTIONS (ABSSI)**

Ayyagari R<sup>1</sup>, Revol C<sup>2</sup>, Tang W<sup>2</sup>, Faust E<sup>1</sup>, Tuttle EG<sup>3</sup>,<sup>1</sup>Analysis Group, Inc., Boston, MA, USA, <sup>2</sup>Analysis Group, Inc., New York, NY, USA, <sup>3</sup>Analysis Group, Inc, Menlo Park, CA, USA

**PSS42 V2 pgA186 BIBLIOMETRIC ANALYSIS OF THE WORLDWIDE SCIENTIFIC PRODUCTION OF ORAL HEALTH**

Simbaqueba E, Zarama P, Robles A, Upegui A, Unicoc University, Bogota, Colombia

**PSS43 V3 pgA186 BIOLOGIC ADHERENCE AMONG PSORIASIS PATIENTS IN THE US MEDICARE POPULATION**

Doshi JA<sup>1</sup>, Takeshita J<sup>1</sup>, Pinto L<sup>2</sup>, Li P<sup>1</sup>, Yu X<sup>1</sup>, Rao PM<sup>3</sup>, Vishwanathan H<sup>2</sup>, Gelfand JM<sup>4</sup>,<sup>1</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>2</sup>Amgen, Thousand Oaks, CA, USA, <sup>3</sup>University of Pennsylvania - The Wharton School, Philadelphia, PA, USA, <sup>4</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, USA

---

#### URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies

**PUK2 V4 pgA186 COMPARATIVE EFFICACY OF INTERVENTIONS FOR OVERACTIVE BLADDER SYNDROME: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**

Owen RK, Tincello DG, Bujkiewicz S, Abrams K, University of Leicester, Leicester, UK

---

#### URINARY/KIDNEY DISORDERS - Cost Studies

**PUK4 V5 pgA186 THE BUDGET IMPACT OF TREATMENT PATHWAY REDESIGN IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS) ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA (BPH)**

Patel S<sup>1</sup>, Garnham A<sup>2</sup>, Nazir J<sup>2</sup>,<sup>1</sup>Astellas UK, Chertsey, UK, <sup>2</sup>Astellas Pharma EMEA, Chertsey, UK

**PUK5 V6 pgA187 EVALUATING THE ECONOMIC IMPLICATIONS OF NONADHERENCE AND ANTIBODY-MEDIATED REJECTION IN RENAL TRANSPLANT RECIPIENTS: THE ROLE OF ONCE-DAILY, PROLONGED-RELEASE TACROLIMUS IN THE UK SETTING**

Muduma G<sup>1</sup>, Odeyemi IA<sup>1</sup>, Pollock RF<sup>2</sup>,<sup>1</sup>Astellas Pharma EMEA, Chertsey, UK, <sup>2</sup>Ossian Health Economics and Communications GmbH, Basel, Switzerland

**PUK6 V7 pgA187 ECONOMIC BURDEN OF ANTIBODY MEDIATED REJECTION FOLLOWING KIDNEY TRANSPLANTATION: COMPARATIVE ANALYSIS USING THE PREMIER HOSPITAL DATABASE**

Irish W<sup>1</sup>, Boscoe A<sup>2</sup>, Ryan MP<sup>3</sup>, Iloeje U<sup>4</sup>, Gunnarsson C<sup>3</sup>, Marks W<sup>4</sup>,<sup>1</sup>CTI Clinical Trial and Consulting Services, Raleigh, NC, USA, <sup>2</sup>Alexion Pharmaceuticals Inc, Cambridge, MA, USA, <sup>3</sup>CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA, <sup>4</sup>Alexion Pharmaceuticals Inc, Cheshire, CT, USA

**PUK7 W1 pgA187 ECONOMIC BURDEN OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE IN CHINA: A REVIEW**

Li X, Yang L, Peking University, Beijing, China

**PUK8 W2 pgA187 USE OF A FRENCH CLAIMS DATABASE TO ESTIMATE REAL-WORLD TREATMENT COSTS OF BENIGN PROSTATIC HYPERPLASIA**

Jouaville SL<sup>1</sup>, DiNicola S<sup>2</sup>, Boutmy E<sup>1</sup>,<sup>1</sup>Cededim Strategic Data, Boulogne-Billancourt, France, <sup>2</sup>Inferential, Paris, France

**PUK9 W3 pgA187 «COST OF ILLNESS» ANALYSIS OF CHRONIC KIDNEY DISEASE IN THE ENTIRE POPULATION OF THE RUSSIAN FEDERATION**

Kulikova A, Serpik VG, Abdrashitova G, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**PUK10 W4 pgA187 COST OF ILLNESS AND THE FACTORS AFFECTING IT IN THE PATIENTS OF CHRONIC KIDNEY DISEASE AT A PUBLIC TERTIARY CARE HOSPITAL**

Ahlawat R<sup>1</sup>, Tiwari P<sup>1</sup>, D'Cruz S<sup>2</sup>,<sup>1</sup>National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, <sup>2</sup>Government Medical College & Hospital, Chandigarh, India

**PUK11 W5 pgA188 LACK OF ADHERENCE TO IMMUNOSUPPRESSIVE TREATMENT IN KIDNEY TRANSPLANT PATIENTS: ESTIMATION OF ASSOCIATED DIRECT MEDICAL COSTS**

Serón D<sup>1</sup>, Alonso Á<sup>2</sup>, Gainza J<sup>3</sup>, Mazuecos A<sup>4</sup>, González E<sup>5</sup>, Kanter J<sup>6</sup>, Callejo D<sup>7</sup>, Fernández-Ortiz L<sup>7</sup>, González E<sup>8</sup>, Toledo A<sup>8</sup>, Muduma G<sup>9</sup>,<sup>1</sup>Hospital Universitario Vall d'Hebrón, Barcelona, Spain, <sup>2</sup>Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, <sup>3</sup>Hospital Universitario Cruces, Vizcaya, Spain, <sup>4</sup>Hospital Universitario Puerta del Mar, Cádiz, Spain, <sup>5</sup>Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>6</sup>Hospital Universitario Dr. Peset, Valencia, Spain, <sup>7</sup>Laser Analytica, Oviedo, Spain, <sup>8</sup>Astellas Pharma SA, Madrid, Spain, <sup>9</sup>Astellas Pharma EMEA, Chertsey, UK

**PUK12 W6 pgA188 COST MINIMIZATION ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENT ON KIDNEY TRANSPLANT PATIENTS**

Petiteau Moreau F<sup>1</sup>, Desbouis C<sup>1</sup>, Hadjadj C<sup>1</sup>, Klett A<sup>1</sup>, Hauville C<sup>1</sup>, Lucats L<sup>1</sup>, Merville P<sup>2</sup>, Etienne I<sup>1</sup>, Tilleul P<sup>3</sup>,<sup>1</sup>University Hospital of Bordeaux, PESSAC, France, <sup>2</sup>University Hospital of Bordeaux, Bordeaux, France, <sup>3</sup>Paris Descartes University, Paris, France

**PUK13 W7 pgA188 COST-EFFECTIVENESS ANALYSIS OF MANAGEMENT OPTIONS FOR SMALL RENAL MASSES: A SYSTEMATIC REVIEW**

Wang Y<sup>1</sup>, Chen Y<sup>2</sup>, Leow J<sup>1</sup>, Levy AC<sup>3</sup>, Chang SL<sup>1</sup>,<sup>1</sup>Brigham and Women's Hospital; Harvard Medical School, Boston, MA, USA, <sup>2</sup>Harvard School of Public Health, Boston, MA, USA, <sup>3</sup>Columbia University, New York, NY, USA

---

#### URINARY/KIDNEY DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

**PUK14 W8 pgA188 SELF-EFFICACY, HEALTH LITERACY AND ADHERENCE TO SELF-CARE BEHAVIORS IN KIDNEY TRANSPLANT RECIPIENTS**

**Campbell ML**<sup>1</sup>, Beardsley RS<sup>2</sup>, Shaya FT<sup>2</sup>, Pradel FG<sup>2</sup>,<sup>1</sup>U.S. Food and Drug Administration, Silver Spring, MD, USA, <sup>2</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA

**PUK15 X1 pgA188 EVALUATION OF MEDICATION ADHERENCE RATE AMONG HEMODIALYSIS PATIENTS: A MULTICENTRIC COMPARATIVE STUDY**

Mateti UV<sup>1</sup>, **Nagappa AN**<sup>1</sup>, Atturi RP<sup>2</sup>,<sup>1</sup>Dept. of Pharmacy Management, MCOPS, Manipal University, Manipal, India, <sup>2</sup>Dept. of Nephrology, KMC, Manipal University, Manipal, India

**PUK16 X2 pgA189 CONCEPTUAL FRAMEWORK IN INTERSTITIAL CYSTITIS / BLADDER PAIN SYNDROME**

**Hawken NA**<sup>1</sup>, DAM C<sup>1</sup>, Nazir J<sup>2</sup>, Aballéa S<sup>3</sup>, Hakimi Z<sup>4</sup>,<sup>1</sup>Creativ-Ceutical, Luxembourg, Luxembourg, <sup>2</sup>Astellas Pharma EMEA, Chertsey, UK, <sup>3</sup>Creativ-Ceutical, Paris, France, <sup>4</sup>Astellas Pharma, Leiden, The Netherlands

---

**URINARY/KIDNEY DISORDERS - Health Care Use & Policy Studies**

**PUK17 X3 pgA189 RETROSPECTIVE STUDY OF UTILIZATION PATTERNS OF OVERACTIVE BLADDER THERAPY IN MEN IN A COMMERCIALY INSURED POPULATION: THE EARLY US MIRABEGRON EXPERIENCE**

**Ng D**<sup>1</sup>, Shelton J<sup>2</sup>, Wei D<sup>1</sup>, Fan A<sup>1</sup>, Berner T<sup>1</sup>,<sup>1</sup>Astellas Scientific and Medical Affairs, Inc., Northbrook, IL, USA, <sup>2</sup>Skyline Urology, Torrance, CA, USA

**PUK18 X4 pgA189 LACK OF ADHERENCE TO IMMUNOSUPPRESSIVE TREATMENT IN KIDNEY TRANSPLANT PATIENTS: ESTIMATION OF ASSOCIATED HEALTH RESOURCE UTILIZATION**

**Serón D**<sup>1</sup>, Alonso Á<sup>2</sup>, Gainza J<sup>3</sup>, Mazuecos A<sup>4</sup>, González E<sup>5</sup>, Kanter J<sup>6</sup>, Callejo D<sup>7</sup>, Fernández-Ortiz L<sup>7</sup>, González E<sup>8</sup>, Toledo A<sup>8</sup>, Muduma G<sup>9</sup>,<sup>1</sup>Hospital Universitario Vall d'Hebron, Barcelona, Spain, <sup>2</sup>Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, <sup>3</sup>Hospital Universitario Cruces, Vizcaya, Spain, <sup>4</sup>Hospital Universitario Puerta del Mar, Cádiz, Spain, <sup>5</sup>Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>6</sup>Hospital Universitario Doctor Peset, Valencia, Spain, <sup>7</sup>Laser Analytica, Oviedo, Spain, <sup>8</sup>Astellas Pharma SA, Madrid, Spain, <sup>9</sup>Astellas Pharma EMEA, Chertsey, UK

**PUK19 X5 pgA189 COMPARATIVE EVALUATION OF PCR-RFLP OF SSU RNA AND COWP GENE FOR DETECTION OF CRYPTOSPORIDIUM SPECIES IN PATIENTS WITH POST RENAL TRANSPLANT DIARRHOEA**


**Ranjan P**, Ghoshal U, Sharma RK, Ghoshal UC, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

**PUK20 X6 pgA189 PRIORITIZATION OF COMPARATIVE EFFECTIVENESS RESEARCH QUESTIONS BASED ON IDENTIFICATION OF THE MOST RELEVANT OUTCOMES TO IMPROVE CLINICAL PRACTICE: AN APPLICATION OF MCDA TO DIALYSIS RESEARCH PLANNING**

**Khoury H**<sup>1</sup>, Nesrallah G<sup>2</sup>, Goetghebeur MM<sup>3</sup>,<sup>1</sup>LASER Analytica, Montreal, QC, Canada, <sup>2</sup>Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada, <sup>3</sup>LASER Analytica & University of Montreal, Montreal, QC, Canada



# RESEARCH POSTER PRESENTATIONS FLOOR PLAN



## Looking for poster presentations online?

The **ISPOR Scientific Presentations Database** is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to [www.ispor.org](http://www.ispor.org) and click the purple "Scientific Presentations" tab.

